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CHAPTER 1
INTRODUCTION
Interest in central nervous system (CNS) started in the 19 th century. Rudolf Virchow
(1821-1902), a German physician, was first to suggest the name „myelin‟ when he described the
sheaths that encircled axons. For several decades research in the field of myelin was dominated
by pathology and continued to make instrumental advancement into the clinical and histological
description of several demyelinating diseases. Many of the disorders with white matter
involvement cannot be placed under the narrow concept of leukodystrophy, which implies
inherited demyelinating disorder. The broader

term “white

matter

disorders” and

“leukoencephalopathies” are defined as all conditions in which predominantly or exclusively
white matter is affected (van der Knaap 2001). Key concepts throughout this dissertation are (1)
demyelination, used when there is loss of myelin; (2) hypomyelination, which means that too
little myelin is formed and this deficiency is permanent; (3) dysmyelination, used when the
process of myelination is disturbed, leading to abnormal, patchy, or irregular myelination.
The underlying genetic involvement is not fully understood in all types of
leukodystrophies, and because phenotypic expression of the same genotype can also be variable,
diagnosis of many leukodystrophies presents a considerable challenge. Leukodystrophies often
express themselves within the first two years of life corroborating with the critical window of
normal myelination (Barkovich 2000; Barker and Horska 2004). The diagnostics of cerebral
white matter disorders was revolutionized by the advent of magnetic resonance imaging (MRI)
in the late 1980s. While leukodystrophies were previously defined based on pathological
findings alone, MRI has provided a powerful tool for investigating the cerebral white matter in
living patients (van der Knaap, Smit et al. 1997). The previously known “classical”
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leukodystrophies have been demonstrated to show characteristic patterns of MRI abnormalities
(Cheon, Kim et al. 2002). MRI offers superior soft tissue contrast, multiple contrast mechanisms
for improved tissue characterization, and artifact-free imaging of the brain stem and cerebellum.
Advanced MR modalities such as diffusion tensor imaging (DTI), magnetization transfer (MTR)
and proton magnetic resonance spectroscopy (H-MRS) are evolving as a primary diagnostic tool
in the evaluation of leukodystrophies. MRI has changed the field entirely with it now possible to
visualize white matter abnormalities in detail in living individuals and to incorporate what is
known regarding the pathologic nature to provide a complete diagnostic description of the
disease.
This dissertation will examine the role of conventional MRI and DTI to further
characterize Pelizaeus-Merzbacher disease (PMD), which is a rare and progressive condition that
is an X-linked recessive leukodystrophy of the central nervous system myelin. Furthermore, this
work will examine the neuropathology of patients characterized by mutations affecting the PLP1
gene and is instrumental in describing how CNS white matter pathology complements
neuroimaging in characterizing PMD.

Pelizaeus-Merzbacher disease
Pelizaeus-Merzbacher disease (PMD) is a rare and progressive condition that is an Xlinked recessive leukodystrophy of the central nervous system myelin.

The underlying

disturbance of myelination in PMD is attributed to the failure to form myelin (Seitelberger 1970;
Seitelberger, Urbanits et al. 1996), rather than to breakdown of preexisting myelin as observed in
multiple sclerosis (MS). PMD is caused by mutations of the proteolipid protein 1 (PLP1) gene
found on chromosome Xq22 and manifests with a clinical heterogeneous phenotype that may
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depend upon the location and type of mutation (Garbern, Cambi et al. 1999; Garbern, Cambi et
al. 1999; Cailloux, Gauthier-Barichard et al. 2000; Hubner, Orth et al. 2005; Garbern 2007). The
functional significance of PLP is its role as a major protein in CNS myelin, making up about half
of the total myelin protein mass (Lees, Samiullah et al. 1984). Serving as an integral membrane
protein, PLP is a structural protein acting as a strut that maintains the morphology of the
intraperiod line of compacted myelin in the CNS (Duncan, Hammang et al. 1987; Boison and
Stoffel 1994; Boison, Bussow et al. 1995; Griffiths, Klugmann et al. 1998). The exact type of
PLP1 mutation dictates the onset and severity of PMD and can be classified according to the
mutational mechanisms, including the deletion/insertion of the entire gene (Pham-Dinh,
Boespflug-Tanguy et al. 1993; Garbern, Cambi et al. 1999; Garbern, Moore et al. 2002), point
mutations that affect splicing or regulation of gene expression and increased dosage of the PLP1
gene (Ellis and Malcolm 1994; Sistermans, de Wijs et al. 1996; Sistermans, de Coo et al. 1998).
In PLP1 related defects of myelination, the clinical severity of PMD varies from the severe
„connatal‟ form (Seitelberger, 1970) that begins during infancy to a much milder variant spastic
paraplegia type 2 (SPG2) which has a relatively normal life span (Saugier-Veber, Munnich et al.
1994; Hudson 2003; Inoue 2004). The clinical description exhibits clinical and genetic
heterogeneity which reflects X-linked recessive traits and distinct myelin pathology that begins
at birth or early in infancy, representing the connatal and classical forms of PMD (Zeman,
DeMyer et al. 1964; Seitelberger 1970; Koeppen, Ronca et al. 1987).
The most severe form, connatal PMD, (Seitelberger 1970) presents at birth or during the
first few weeks of life with pendular nystagmus, hypotonia, respiratory distress, pharyngeal
weakness and stridor. Affected males later develop significant spasticity and have little voluntary
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muscle control. Cognitive impairment is likely. Pharyngeal weakness causes swallowing
difficulties, and infants can have stridor, optic atrophy and seizures (Garbern 2005).
Classical form (Pelizaeus 1885; Merzbacher 1910) is the most common form of the
disease, also present in infancy, usually within the first two to four months of life. Affected
males develop nystagmus, hypotonia with lower extremity weakness, trunk and limb ataxia, and
head titubation. The motor milestones are delayed, and children develop spastic quadriparesis.
Most children never walk independently. Language function can be normal, although dysarthric,
and cognitive impairments are common. The affected patients do not exhibit respiratory
involvement and can survive at least until the sixth decade of life (Garbern 2005). In classical
PMD, PLP1 duplications comprise of 65-70% of the cases with mild to moderate severity
(Inoue, Osaka et al. 1996; Sistermans, de Wijs et al. 1996; Inoue 2004). The PLP1 gene dosage
effect and clinical severity are linearly correlated indicated that the PLP1 gene is dosage
sensitive. Studies have found that three or more copies of the PLP1 gene in patients have a more
severe form of PMD (Wolf, Sistermans et al. 2005), while those that have a deletion of the PLP1
gene or SPG2 have a relatively mild form of PMD.
A subset of patients with null mutations presents into the first 5 years of life with mild
spastic quadriparaesis, mostly affecting the lower extremities (Garbern, Moore et al. 2002).
Patients with the null syndrome are able to ambulate despite the increased tone. They have
ataxia, but do not exhibit pendular nystagmus. While they have mild to moderate cognitive
difficulties, language skills develop initially. The PLP1 null syndrome is further distinguished
from other forms of PMD by the presence of a mild demyelinating peripheral neuropathy
(Garbern 1999).
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White matter
The CNS tissue is comprised of grey matter structures and an extensive array of
connecting white matter tracts. The white matter is made up of myelinating axons, a large
number of glial cells and vasculature that supply nourishment. The glial cells include
oligodendrocytes, which are myelin-forming cells, astrocytes, which are responsible for the
blood-brain barrier and other functions, and microglia cells, which have phagocytic function.
Understanding the complexity of glial cell function is evolving. On a dry weight basis, 40-50%
of white matter is myelin (Baumann and Pham-Dinh 2001).
Myelin is a modified plasma membrane that spirally wraps and insulates the axons (Fig
1). Each myelin sheath is composed of multiple segments which are modified extensions of
oligodendrocytes. Myelination in the CNS is differs from that of the PNS in that a single
oligodendrocyte can myelinate up to 50 different internodal segments on neighboring axons. The
myelinated axons under electron microscopy (Arroyo and Scherer 2000) shows the myelin
sheath composed of multiple plasma membrane layers with the opposed membranes forming the
intraperiod line with a the thin space between the adjacent myelin leaflets contiguous with the
extracellular space (Fig. 1). The myelinated axons are completely covered by myelin except in
<1µm gaps known as nodes of Ranvier that contain a cluster of voltage-gated sodium channels
essential for saltatory conduction of electrical impulses (Black, Kocsis et al. 1990; Arroyo and
Scherer 2000; Arroyo, Xu et al. 2001).
To discriminate between the various mechanisms involved in the sorting and transport of
myelin components and how they related to disease pathogenesis, it is relevant to first provide
insight into the molecular composition of the myelin sheet. During myelin formation, OLGs
mature in a process in which development stages can be identified (Fig 1.1). The cells
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differentiate from bipolar progenitor cells (O2A stage) to a cell with branched processes (GalC
stage), when the earliest myelin specific protein 2‟, 3‟-cyclic nucleotide 3‟ phosphodiesterase is
expressed (Pfeiffer, Warrington et al. 1993). Maturation into myelin forming OLGs and the
assembly of the myelin sheath as such is characterized by the sequential expression of the
proteins that make up the myelin, including myelin-associated glycoprotein (MAG), myelin
basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG)
Pfeiffer, Warrington et al. 1993).
Myelin can be considered to be subdivided into a compact region, responsible for its
physical insulation properties and a non-compact region called the radial component
(Arroyo and Scherer 2000). The compact myelin is formed by the apposition of the external
faces of the membrane of the myelinating cell, forming the intraperiodic line; the apposition of
the internal faces, followed by extrusion of cytoplasm, gives rise to the formation of the major
dense line (Fig 1.2). A tight junctional array is located between compact and non-compact
myelin, which likely serves as a diffusion barrier between these myelin subdomains (Gow,
Southwood et al. 1999; Morita, Sasaki et al. 1999). The compact region is enriched with
glycosphingolipid galactocerebroside and sulfatide. In this region, the major myelin proteins are
proteolipid protein (PLP) and myelin basic protein (MBP), accounting for 50% and 30% of the
total protein mass, respectively (Garbern 1999).

PLP1 gene and proteolipid protein
The PLP1 gene is composed of seven exons that extend over 17 kb of genomic sequences
located on chromosome Xq22 (Diehl, Schaich et al. 1986). Expression of PLP1 dominates in the
CNS OLGs lineage and correlates with the onset of myelination that begins during the 3rd
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trimester of pregnancy in humans (Inoue 2004). The alternative splicing of the PLP1 gene
generates two proteins, PLP and DM-20 which lacks amino acids 116-150 of the PLP sequence
(Nave, Lai et al. 1987). The proteoplipid protein is the major integral membrane protein of CNS
myelin (Griffiths, Klugmann et al. 1998). PLP spans the membrane four times (Fig. 1.3) and is
highly hydrophobic with 50% hydrophobic amino acids (Popot, Pham-Dinh et al. 1991; Weimbs
and Stoffel 1992). As a structural protein, PLP plays a major role in assembly and stabilization of
the myelin sheath in that the proteins brings about the correct apposition of the extracellular
myelin leaflets, thereby stabilizing the multilayer membrane structure after compaction (Duncan,
Hammang et al. 1987; Boison and Stoffel 1994; Boison, Bussow et al. 1995; Griffiths,
Klugmann et al. 1998; Bizzozero, Bixler et al. 2001; Rosenbluth, Nave et al. 2006). Surprisingly,
mice lacking PLP1 and DM20 are not critical for oligodendrocyte differentiation and assembly
of CNS myelin (Boison, Bussow et al. 1995; Klugmann, Schwab et al. 1997). However,
ultrastructural examinations of myelin in both knockout mice and patients with a deletion of the
PLP1 gene have shown myelin to be physically fragile (Boison and Stoffel 1994; Klugmann,
Schwab et al. 1997). Furthermore, in hereditary spastic paraplegia and the absence of PLP in
mice and PMD patients not only causes structural instability, but causes axonal injury resulting
in late-onset axonal swellings and degeneration without any significant reduction in myelin
(Garbern, Moore et al. 2002; Deluca, Ebers et al. 2004). PLP1 point mutations results in
premature arrest of OLGs differentiation and early death, while overexpression of the normal
PLP1 gene in transgenic mice leads to severe dysmyelination (Kagawa, Ikenaka et al. 1994;
Readhead, Schneider et al. 1994). In humans, a variety of mutations, including missense
mutations (Cailloux, Gauthier-Barichard et al. 2000), deletions (Raskind, Williams et al. 1991;
Garbern, Cambi et al. 1997; Garbern, Yool et al. 2002) and duplications (Wolf, Sistermans et al.
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2005) are known to cause the dysmyelinating disorder PMD and spastic paraplegia (SaugierVeber, Munnich et al. 1994; Inoue, Khajavi et al. 2004). Gene duplications of the human PLP
locus are responsible for the majority of the cases leading to enhanced expression of the PLP1.
Although it is evident that PLP plays a vital role in myelin assembly and maintenance, on a
functional and molecular level, its precise role remains undefined.

Trafficking of PLP
PLP and its alternatively spliced isoform DM20 are synthesized in the endoplasmic
reticulum (ER) and subsequently transported via vesicles to the Golgi, followed by transport to
the compact internodal region of the myelin sheath. Upon removal from the Golgi, PLP1 is now
assembled together with cholesterol and galactocerebroside-enriched membrane domains in
myelin rafts during transportation to be inserted into oligodendrocytes membrane.

Point

mutations, mostly resulting from missense amino acid substitutions comprised of 15- 20% of the
genetic abnormalities responsible for PMD. Clinical phenotypes are quite variable extending from
mild (SPG2) to severe (connatal PMD). Majority of PLP1 point mutations cause more severe
dysmyelinating and demyelinating disease rather than that caused by null mutations that suggest
the absence of functional PLP is not involved in the proper maintenance of myelinating axons and
not from a cytotoxic effect of mutant protein. Mutant PLP has been demonstrated that misfolded
protein accumulates in the ER inducing the unfolded protein response (UPR) (Gow, Southwood et
al. 2002; Southwood, Garbern et al. 2002) and not allowing the protein to reach the Golgi to
interact with cholesterol and other lipids into myelin rafts (Simons, 2000). Because of the
retention and failure to transport PLP the oligodendrocyte cell membrane this mechanism is
considered to cause premature oligodendrocyte death (Gow, Southwood et al. 1998). The
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trafficking of both PLP/DM20 results in a severe clinical phenotype compared to a milder
phenotype (SPG2), which results from an accumulation of PLP1 and not DM20 (Southwood,
Garbern et al. 2002). Protein misfolding and activation of the UPR is not an unknown entity
unique to just PMD, but it is also found in other neurodegenerative diseae such as Alzheimer‟s
disease and Parkinson disease (Hoozemans, Veerhuis et al. 2005; Hoozemans, van Haastert et al.
2007; Hoozemans, van Haastert et al. 2009). Unlike missense mutations, there are no spontaneous
animal models for PLP1 gene duplications, but transgenic mice have been generated by (Kagawa,
Nakao et al. 1994; Readhead, Schneider et al. 1994). The homozygous mice with high PLP1 gene
dosage exhibit a severe early-onset dysmyelination with increased oligodendrocyte cell death,
which maybe due to the accumulation of PLP1 in late endosome/lysosomes. The exact
pathogenesis is not fully understood, but the imbalance in transport and assembly of myelin
constituents adversely affects myelin assembly in the Golgi (Garbern 2007). The severe
dysmyelinating pattern and clinical phenotype found in homozygous mice have also been
identified in patients with three or more copies of PLP1 (Wolf, Sistermans et al. 2005). On ther
other hand, hemizygous mice with a lower copy number develops normally with no clinical signs
until later in life. The clinical signs develop later in life due to the late onset demyelination and
axonal shperoids and degeneration (Anderson, Schneider et al. 1998). Taken together, the
pathologic and clinical severity is similar to that of PLP1 knockout mice relfecting the sensitivity
to changes in gene dosage of „too much or none at all.‟

Magnetic resonance imaging investigation of white matter disorders
MRI is very sensitive in showing signal abnormalities in the white matter. Apart from myelin
disturbances (hypomyelination, dysmyelination, and demyelination), damage to other components of
the white matter may contribute to the observed signal abnormality. These include edema, seen for
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instance in conjunction with increased vascular permeability, and gliosis, which occurs when
astrocytes react to diverse forms of injury (van der Knaap 2001).
T1-weighted images are used to assess the anatomic structures. During the early phases of
myelination, small amounts of myelin are better visualized on T1-weighted images. On these images,
normally myelinated white matter appears bright and cerebrospinal fluid (CSF) is black. Pathological
white matter gives a decreased signal and appears dark on T1-weighted images.
T2-weighted images are superior in showing the pathological processes of white matter. For
subjects aged 9-10 months or beyond, T2-weighted images are more useful in evaluating the stage of
myelination. Normal myelinated white matter appears dark and CSF is bright on these images.
Pathology in the white matter leads to an abnormally high signal on T2-weighted images.
FLAIR (Fluid attenuated inversion recovery) is a T2-weighted sequence, where the signal of
the free fluid, e.g. CSF, is nullified. In these images, the CSF is black and myelinated white matter is
dark. If white matter is pathologic, it appears hyperintense and especially periventricular lesions are
easily distinguished. The cystic nature of the lesions is also revealed by FLAIR images.
As the white matter myelinates, it changes from hypointense (dark) to hyperintense (bright)
relative to gray matter on T1-weighted images and from hyperintense to hypointense relative to gray
matter on T2-weighted images. These changes in signal intensity are caused by increasing brain lipid
concentration and decreasing water content (Barkovich 2000). The myelin signal appears earlier on
T1-weighted images. In a newborn, myelin is seen in the posterior limbs of the internal capsules and
in the dorsal brainstem (Fig 1.4). During the first year of life, progressive myelination is seen, with
sensorimotor and visual pathways maturing first and subcortical association areas maturing last (Fig
1.4) (Barkovich 2005). By the age of 24 months, myelination appears essentially mature in MRI
(Barkovich 2000).
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Myelination Milestones
Myelination within the CNS begins approximately the fourth month of fetal development
at the cervical levels of the spinal cord. In the brain, myelination begins approximately the sixth
month of gestation and is known to be limited to the region of the basal ganglia. The trend for
myelination evolves more rapidly in areas of the brain linked to functional systems that are
utilized during early periods of life, such as motor behavior (Barkovich 2005). Myelination
progress is from caudal to cephalad and from dorsal to ventral. Thus, the occipital lobes of the
cerebral hemispheres myelinate early while the frontal lobes myelinate late. White matter
changes are seen best on T1-weighted images during the first six to eight months of life and T 2weighted images are best to evaluate myelination between six and eighteen months of life.
T1-weighted MRI of maturing white matter found in figure 1.4 shows the striking feature
that much of the brain remains unmyelinated in a neonate. However, an increase in white matter
signal intensity is observed in the newborn at the level of posterior aspect of the posterior limb of
the internal capsule. Around 5 month of age, the corticospinal tracts of the posterior limb of the
internal capsule becomes more pronounced expressing hyperintensity of white matter seen
throughout both the anterior and posterior limbs of the internal capsule. Continuing on to the 8th
month, the deep white matter appears hyperintense, however the subcortical white matter from
the frontal to occipital poles remains hypointense (Barkovich 2005). The peak of myelin
formation rapidly occurs during the first 24 months of postnatal development, however,
myelination can precede slowly through the second decade of life in some cortical fibers,
predominately those tailored to associative areas (Baumann and Pham-Dinh 2001).
An understanding of the development and structure of myelin is helpful in explaining the
change in white matter signals during brain development and thus in improving the reliability to
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differentiate demyelination vs. dysmyelination disorders. Furthermore, the location of myelin
disturbances is critically important to disease phenotype. Often abnormal MRI signal intensities
may precede clinical signs of the disease. Leukodystophies such as PMD are aggressive and can
produce distinct patterns of abnormalities on MRI that can help distinguish them.
The myelination milestones of various white matter structures (Table 1) becomes pivotal
in understanding and describing cerebral white matter abnormalities found in many inherited
diseases. Among the “classical” leukodystrophies, metachromatic leukodystrophy, Krabbe
disease, X-linked adrenal leukodystrophy are lysosomal and peroxisomal diseases in which
progressive demyelination occurs in both the CNS and the PNS (Melhem, Barker et al. 1999;
Suzuki, Armao et al. 2001; Gieselmann, Franken et al. 2003). Alexander disease is a primary
astrocytic disorder caused by dominant mutations of the GFAP gene (Brenner, Johnson et al.
2000). Canavans disease is an organic acid disorder with spongiform leukoencephalopathy
(Matalon and Michals-Matalon 2000) and last Pelizaeus Merzbacher disease is an X-linked
hypomyelinating disorder that has been well described by (Seitelberger 1970; Ulrich and
Herschkowitz 1977; Seitelberger 1995).

MRI characteristics of Pelizaeus-Merzbacher disease
An appreciation of the normal appearance of unmyelinated and myelinated white matter
structures on brain MRI is helpful for understanding imaging studies of infants and children with
a dysmyelinating leukodystrophy (Barkovich 2005). In normal full-term infants, myelination is
usually evident on MRI in the pons and cerebellum, and by the age of three months, normal
infants show myelination in the posterior limb of the internal capsule, splenium of the corpus
callosum, and optic radiations (Barkovich 2005). Absence of these MRI findings suggests the
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diagnosis of a dysmyelinating syndrome such as PMD. The brain MRI of older children with the
PMD often reveals diffuse hypomyelination marked by increased signal intensity in the cerebral
hemispheres, cerebellum, and brainstem on T 2-weighted or fluid-attenuated inversion recovery
(FLAIR) sequences (Fig 1.5). No clear correlation between genotype, clinical phenotype, and
MRI phenotype has been established for PMD, but reasonable assessments can be inferred.
However, some experts have noted an inverse correlation between the amount of myelin present
and the clinical disease severity (van der Knaap, Breiter et al. 1999). As an example, no myelin
is present at all in some infants with connatal PMD, the most severe form of PMD (van der
Knaap, Breiter et al. 1999). In patients with the classic PMD phenotype, the white matter
abnormalities on MRI have been divided into three subtypes (Nezu, Kimura et al. 1998; Nezu,
Kimura et al. 1998):
1. Type I: diffuse abnormality in the hemispheres with lesions affecting the corticospinal
tracts; this type was found in patients with a PLP1 duplication.
2. Type II: similar hemispheric lesions without corticospinal involvement.
3. Type III: patchy hemispheric involvement. The patchy areas of myelin forming the
"tigroid" pattern are not readily apparent on neuroimaging in most patients (Takanashi,
Sugita et al. 1999).
Patients with the SPG2 phenotype are said to have less severe abnormalities on brain MRI
compared with the PMD phenotype. However, the reported abnormalities on T 2 MRI in SPG2
range from discrete or patchy hyperintensities to more diffuse leukoencephalopathy (Cambi et
al., 1995; Hodes et al., 1999).
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Significance
The most important clinical tools for investigating white matter disorders in living
patients are magnetic resonance techniques to evaluate macroscopic structural changes and the
integrity of the microstructural infrastructure. With modern MRI techniques, we can now
complement that which is examined pathologically to monitor the pathogenesis and response to
therapeutic intervention in white matter disease.
Imaging in living patients can be used to detect and quantify gray- and white-matter
abnormalities on both macrostructural and microstructural levels. Conventional structural
magnetic resonance imaging (MRI) reveals the size, shape, and tissue composition (gray vs.
white matter) of the brain and its constituent parts. Alterations of normal appearing white matter
(NAWM) is of great importance because its true patho-physiological significance is not
completely understood. An immediate goal is to provide a firmer basis of magnetic resonance
techniques as a tool to reveal the integrity of white-matter connectivity.
The primary parameters accessible from DTI, the directional diffusivities, are often
combined into summary parameters sensitive to tissue pathology and morphology. DTI can make
reasonable assessments into the integrity of white matter connectivity and the associated
pathological conditions that perturb the higher organization of the CNS by monitoring the
changes in diffusion of water over the course of disease progression. However, such parameters
lack specificity to detect and differentiate axon vs. myelin degeneration alone, which warrant the
application of MRS. The high sensitivity of DTI to microscopic structural tissue changes can be
applied to the development, pathology and monitoring of neurological diseases. The degree of
myelination, axonal swelling, microglia proliferation and reduced extracellular matrix will
influence the behavior of microscopic water diffusion and therefore, reflect the pathological

15
changes as they take place in real time. Magnetic resonance imaging techniques can make
reasonable assessments into the pathological conditions of PMD. The goal is to provide a basis
for the application of magnetic resonance techniques such as DTI as tools to evaluate the
microstructural architecture of axonal pathology and myelin degeneration not only in the
pathogenesis of PMD, but also in other diverse groups of dysmyelinating and demyelinating
disorders.

Hypothesis
The central hypothesis is that novel MRI techniques may provide insight into
differentiating between axonal pathology & myelin degeneration, in vivo, in patients with PMD.
In white matter tracts, water diffusion is greater parallel to the axon than perpendicular to it, due
to the presence of directional subcellular structures that include axon membranes, cytoplasm
filaments that comprise the axonal cytoskeleton and the myelin sheath with act as barriers to
diffusion. We propose that axonal damage will cause a decrease in parallel diffusivity and
fractional anisotropy caused by a decrease in the lengths of the axons as axons degenerate, but
changes may only be measurable at the distal ends of the major neuronal pathways. In addition,
dysmyelination may also cause increased radial diffusion if increased free water is present
between the normally dehydrated leaflets comprising compact myelin or if the packing density of
axons is increased due to the thinning of myelin sheaths.

AIMS OF THE STUDY
One of the objectives in current MRI research of white matter diseases with axonal
pathology and alterations in myelin structure and function is to provide more sensitive and
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specific markers of the biological effects of the disease as well as better monitor disease
progression and response to treatment. There is currently no non-invasive modality capable of
assessing the axonal and myelin components explicitly. However, a number of MR techniques
are available that allow the study of these structures by indirect methods.
Specific Aim 1: To investigate structural MRI studies to quantify and compare the relative
volumetric proportions of white matter of the brain in children and adults with PMD to a functional
disability score. Volumetric analysis will provide an important contribution to our understanding of
the severity of PLP1 gene mutations correlated with functional disability score assessment of
patients. In this MRI study, volumetric analysis is critical to our understanding of the
neuroanatomical development in PMD. Region of interest not only includes a global perspective of
cerebral white matter, but also to consider focal white matter regions such as the sensorimotor area
confined to the pre and post central gyrus. Investigating white matter volumes from a diffuse and
focal perspective may provide a correlation to clinical phenotype found in PMD. A further aim will
be to measure the intercaudate distance, to validate the whole brain volumetric analysis and to serve
as a validation or potential substitution when demarcation of white vs. grey matter become too
difficult to discern.
Specific Aim 2: To quantitatively investigate the parameters of DTI in patients with
genetically confirmed PMD, characterizing the microstructural changes that may have significant
therapeutic implication. The parameters of DTI analysis will validate specific markers of axonal
damage and myelin degeneration regarding the pathogenesis of PMD. This method will be
instrumental in assessing particular white matter pathways such as the corticospinal tract, a
prominent descending motor pathway and the dorsal columns which include assemblies of major
ascending sensory fibers. A further aim is the reconstruction of the motor and sensory pathways
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using DTI as an in vivo method for mapping white matter fiber trajectories and measuring the
density of the axonal fibers. The goal of DTI is to characterize WM tissue such that DTI parameters,
unique in their ability to probe tissue microstructure, provide a greater degree of sensitivity and/or
specificity for pathologic tissue changes than what conventional MRI is able to provide. The goal of
fiber tractography is to map the brain‟s network of interconnections and establish connectivity
patterns between subcortical areas involved in motor movement.
Specific Aim 3. To perform a neuropathologic examination on patients clinically
diagnosed with Pelizaeus-Merzbacher disease. Exact type of PLP1 mutation dictates the onset
and severity of PMD and can be classified according to the mutational mechanisms, including
the deletion of the entire gene, point mutations that affect splicing or regulation of gene
expression and increased dosage of the PLP1 gene. The objective is to examine in particular the
brain pathology of PMD patients that have a range of mutational mechanisms. The white matter
structure of particular interest is the corpus callosum. The reason extends from preliminary
results of our diffusion tensor imaging analysis demonstrating a 107% increase in radial
diffusion compared to age match control subject.
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Figure 1. Left: The relationship between a oligodendrocytes and myelinated nerve fibers in
the CNS. A single oligodendroctye is capable of myelinating up to 50 internodal segments.
Right: The ultrastructure of a myelinated fiber. (a) The EM shows an axon (a) and its
compact myelin sheath (m). (b) This EM shows that the compact myelin sheath is composed
of alternating major dense and intraperiod lines (Arroyo and Scherer 2000)

Figure 1.1 Illustrations of the various stages of oligodendrogenesis. (Woodruff, et al. 2001)
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Figure 1.2 Composition of myelin. The myelin membrane is composed of repeated layers
with protein-lipid-protein-lipid-protein structure. Glycolipids and cholesterol are located at
the extracellular faces and phospholipids at the cytoplasm (intracellular) faces of the lipid
bilayer. In compact CNS myelin, MBP and PLP are the major protein and in the PNS P0 and
PMP22 are the major proteins. The closely apposed external faces of the membrane form the
double intraperiod lines. The fused internal faces of the myelin membrane form the major
dense lines. Modified from (Baumann and Pham-Dinh 2001)
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Figure 1.3 Proposed model for the secondary structure of PLP as it lies
in the lipid bilayer. PLP is a transmembrane protein with two
extracellular loops and one intracellular loop with its N- and C- termini
facing the cytoplasm, The PLP specific region (blue) differentiates PLP
from DM20. Known PLP1 mutations are shown with the most severe
phenotype (red) at a single amino acid position. Mutations that lie in the
large second extracellular loop can lead to abnormal crosslinking that
result in retention of the mutated PLP1 in the endoplasmic reticulum
(Garbern 2007).
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Figure 1.4 MRI changes of a normal pattern of myelination at the level of the basal
ganglia. (A, B) Neonate MRI shows that myelination onT1-weighted image (A) and
T2-weighted images (B) is limited to the posterior limb of the internal capsule at
this level (black arrow). (B) Same patient shown in panel A. (C, D) of a 5-monthold patient shows hyperintensity in the entire internal capsule, optic radiations, and
splenium of the corpus callosum. (D) Same patient shown in panel C shows
hypointensity limited to the posterior limb of the internal capsule and a portion of
the optic radiations. (E, F) 8-month-old patient shows hyperintensity in all white
matter except the immediate subcortical regions. (F) Same patient shown in panel
(E) shows hypointensity in the entire corpus callosum, the entire posterior limb of
the internal capsule, and part of the anterior limb of the internal capsule. (G) 12month-old patient shows hypointensity in the entire internal capsule, in the
subcortical white matter of the motor cortex, and in the subcortical white matter of
the visual cortex. (H) 18-month-old patient shows hypointensity in most of the deep
white matter but lack of maturity of subcortical white matter. (I) Image of a 24month-old patient show that essentially all white matter is hypointense. (Barkovich,
2000)
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Table 1. Modified from Barkovich, AJ. Pediatric Neuroimaging. 3 rd ed. Lippincott
Williams & Wilkins Philadelphia 2000 pg. 38

24

Figure 1.5 (a) Normal. Phenotypic expression is quite variable with the (b) classical form (i.e.
duplications) exhibiting a high T2 signal located periventricularly with small foci of less
affected areas of preserved myelin (a “tigroid” pattern). (c) Severe „connatal‟ form generally
exhibits severe hypomyelination reflecting the reduced T 1 signal and a diffuse high T2 signal,
whereas (d) the mild null mutation consists of a relatively normal T 1 and T2 signal, although
periventricular hyperintensity may persists, but not always evident.
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Chapter 2
NEURORADIOLOGIC CORRELATES OF CLINICAL
DISABILITY AND PROGRESSION IN PELIZAEUSMERZBACHER DISEASE
Pelizaeus-Merzbacher disease (PMD), an X-linked dysmyelinating disorder, is caused by
mutations in the gene encoding proteolipid protein (PLP1), the major structural protein in central
nervous system (CNS) myelin. Patients with PMD display a variety of neurological signs and
symptoms, including spastic paraparesis, nystagmus, cognitive and visual impairment, and may
also have a peripheral neuropathy. The majority of patients with PMD have a variable sized
duplication of a region of the X-chromosome containing the PLP1 gene, suggesting that
overexpression of PLP1 in oligodendrocytes is the cause of the disease. More than 100 point
mutations in the PLP1 coding region have also been identified in patients with PMD, however,
accounting

for

approximately

15-25%

of

cases

(Hodes,et

al.

1993)

see

http://www.med.wayne.edu/Neurology/plp.html), and have been shown to have a variety of
deleterious effects on oligodendrocyte function and myelination. Although the disease is both
genetically and phenotypically variable in humans, its pathogenesis in rodent, canine, and pig
models has been convincing shown to be a result of dysmyelination.
Brain MRI studies in patients with PMD have demonstrated patterns consistent with
hypomyelination, both in patients with duplications and in patients with point mutations. A study
by Garbern and coworkers has also shown that some patients with PMD caused by a PLP1 null
mutation, have decreased levels of N-acetylaspartate (NAA) due to a length-dependent axonal
degeneration. In contrast, a study of patients with PLP1 duplications has found increased brain
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levels of NAA. These MRI studies have not yet delineated a common pathogenic mechanism in
PMD, and have not provided a framework to correlate the clinical phenotype of patients to their
underlying genotype.
In our current work we have analyzed the clinical phenotypes and MRI scans of 49 male
patients with PMD and 10 female carriers for whom the PLP1 genotype had been determined.
Nine patients had PLP1 duplications, two had PLP1 triplications, while the other 50 individuals
had one of 29 different PLP1 point mutations. To estimate the clinical severity of these patients
we developed a 32-point functional disability scoring system, based on a scale for analyzing
patients with ALS, and validated it for inter-rater reliability in 22 patients with PMD. We then
quantified total brain volume, white matter volume, inter-caudate ratio, and corpus callosum
volume for our cohort of patients using conventional T1- and T2-weighted MRI sequences as well
as a three-dimensional volumetric radiofrequency spoiled gradient echo (SPGR) series. Taken
together, our data demonstrate that decreased white matter volume is a common finding for all
the PMD patients in this cohort, regardless of genotype. In addition, clinical severity, measured
by our functional disability scoring system, is correlated with white matter volume, inter-caudate
ratio and corpus callosum volume. Although there are multiple genetic and molecular
mechanisms causing PMD in this cohort, these data imply that white matter atrophy is the major
pathological determinant of the clinical disability in most patients.
Materials and Methods
PMD patients
Our study population included 45 males and 10 females with known PLP1 mutations. The
patients were analyzed serially from our population of patients with known PMD and selected
based on their willingness to participate in this study. The age of each individual at the time of
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MRI analysis, their functional disability score, and PLP1 mutation are listed in Table 2.3 Nine
patients had PLP1 duplications, two had PLP1 triplications, while the other 50 individuals had
one of 29 different PLP1 point mutations. Seven patients were between 4 and 5 years of age, 7
were between 5 and 10 years of age, 12 were between 10 and 20 years of age, 18 were between
20 and 40, and 10 were older than 40 years of age. The age of one patient at the time of analysis
was not known.
Inter-caudate Ratio
The inter-caudate distance (ICD) and transverse skull diameter (TSD) were measured
from the most caudal axial T1 weighted MRI image for each of the 55 PMD patients in our study.
The ICD was defined as the linear distance on this image between the medial borders of the head
of the caudate nucleus; the TSD was defined as the distance separating the inner table of the
skull on this same image. The inter-caudate ratio (ICR) was then calculated by dividing the ICD
by the TSD at the same axial section level, as described previously by Caon and co-workers
(Caon, Zvartau-Hind et al. 2003). NIH image was used to perform all measurements. A set of
typical measurements is shown in Figure 2.
MR imaging acquisition and processing for volumetric measurements
Patients were evaluated with routine clinical brain MR image scans (T 1-weighted and T2weighted sequences) and three-dimensional volumetric radiofrequency spoiled gradient echo
(SPGR) series at Children‟s Hospital of Michigan on a GE-Sigma 1.5 tesla scanner (General
Electric, Milwaukee, WI), and their total brain volume, white matter volume and grey matter
volume measured from these scans. Patients were excluded from this analysis because the
contrast between grey and white matter was insufficient for volume segmentation. Four examples
of coronal sections from SPGR series with varying grey matter-white matter contrast are shown
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in Figure 2.4d. Volume segmentation could not be performed from scan is part d of this figure
because of lack of contrast. The raw, GE-sigma-formatted image data from these scans were then
transferred to Apple Macintosh Power PC workstation, and the SPGR image data were imported
into the program NIH 1.62 for visualization, processing, and quantitative analysis. DICOM
images were also obtained and were imported into ImageJ (version 1.32j) to partition the series
into an ordered 124 contiguous slices. The scale for each slice was set to 10.666 pixels per
centimeter, 16 bit unsigned with dimensions of 256 X 256.
To prepare the stacks for volumetric measurements, non-brain structures, including the
skull, dura, subarachnoid spaces, ventricles, cerebellum, and brainstem were excluded from the
region of interest (ROI) by manually tracing around them using the NIH program 1.62 as shown
in Figure 2.1. The color threshold was manually adjusted for each slice to insure accurate
segmentation of white and grey matter boundaries. This methodology was used to measure the
ROI for each of the 62 slices available for each MRI scan. The brain volumes are expressed in
units of cubic centimeter.
Corpus callosum area measurements
The corpus callosum area was analyzed in 36 patients from a mid-sagittal section in which the
genu, body, and splenium of the corpus callosum could be visualized. The corpus callosum area
was measured using the program NIH 1.62 as described above by manually tracing around the
corpus callosum and the area expressed in square centimeters.
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Results
White matter atrophy accounts for brain atrophy in patients with PMD
Comparison of total brain volume to white matter volume for 46 patients with PMD,
shown in Figure 2.2, demonstrates a linear relationship (Pearson r =.91, P=<0.0001). Since this
analysis includes patients with different ages that could confound this relationship, we also
plotted white matter volume against patient age. As shown in Figure 2.3, there is no significant
correlation between white matter volume and patient age. These data thus suggest that white
matter atrophy is the major pathological feature in PMD for patients of all ages and mutation
type.

A scoring system to measure functional disability in patients with PMD
In order to determine whether changes in white matter volume are associated with
clinical disability in patients with PMD, we developed and validated a simple and reproducible
clinical scale adapted from a scale used for patients with ALS (Cedarbaum, Stambler et al.
1999). This functional scale (0 to 32) shown in table 2 (also, see Appendix B), measures the
ability of patients to perform routine tasks of daily living, such as feeding, bathing, dressing, and
walking. The scoring system does not depend on any specific disease process or neurological
sign, and can be assessed from a short interview with the patient‟s caregiver. Using this scale
four neurologists at Wayne State University School of Medicine have estimated the functional
disability of a group of 22 patients with genetically confirmed PMD.
The inter-rater reliability of this scoring system, shown in Table 2.1 and 2,2, is greater
than 95%, and is thus quite reliable. The scores, however, shown in Table 1 (also, see Appendix
B), suggest that functional disability is not equally distributed throughout the possible variable
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range, but instead occurs in 3 clusters: 0-10 (severe); 10-20 (moderate); and 20 and above (mild).
Interestingly, these clusters probably represent patients with connatal PMD, classic/transitional
PMD and progressive spastic paraparesis, similar to the categories originally proposed by
Seitelberger, 1970.

The functional disability score (FDS) is correlated with white matter volume in patients
with PMD
A comparison of white matter volume to that of the patient‟s functional disability score
(FDS) is shown in Figure 2.5. As can be seen from this data, white matter volume is positively
correlated to the FDS (Pearson r= 0.50, P < 0.0001) suggesting that white matter atrophy is a
major cause of clinical disability in PMD for patients of all ages and mutation type.

The FDS is correlated with the inter-caudate ratio (ICR) in patients with PMD
To establish a simple MRI metric to follow PMD disease progression, and to confirm the
relationship of white matter atrophy and functional disability described above (Fig 2.6), we
measured the inter-caudate ratio (ICR) for all 55 PMD patients, and compared it to their
functional disability score as shown in Figure 2.7. The ICR has been used previously as an MRI
metric in patients with multiple sclerosis (MS), and has been shown to correlate with disability in
this disease as measured by the expanded disability scoring system (EDSS), suggesting that it is
well suited for analyzing diseases of white matter. As can be seen in the figure the ICR is
positively correlated to the FDS (Pearson r=-0.35, P=< 0.0001), further suggesting that white
matter atrophy is a cause of clinical disability in PMD for patients of all ages and mutation type
(Fig 2.6).
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The FDS is correlated with corpus callosum area in patients with PMD
As an additional check on our data relating white matter atrophy to functional disability
(Fig 2.9), we measured the area of the corpus callosum at its midpoint for 36 PMD patients for
which this MRI section was available (Fig 2.8). Since the corpus callosum is the largest white
matter track in the brain, the functional disability of PMD patients should be correlated with
demyelination and thus atrophy within this structure.

Discussion
MRI has been proven to be instrumental in the diagnostic work-up in cases of
leukodystrophies (van der Knaap and Valk 1995) Most individual leukodystrophies have distinct
patterns of MRI abnormalities that maintain white matter region consistency among patients with
the same disorder. Distinctive MRI pattern of leukodystrophies have been well documented
(André, Monin et al. 1990; van der Knaap 2001; Barker and Horska 2004; Phelan, Lowe et al.
2008; Kohlschutter, Bley et al. 2010). The MRI pattern that exists among patient groups with the
same disorder is not applicable to PMD, which expresses a rich heterogeneous pattern among
patients with duplications among the (4) descriptive classes of PMD, not including the
interfamily heterogeneity.
These results demonstrate the sensitivity that MRI technology imposes in detecting
clinically relevant changes or monitoring the progression of the disease or a response to
therapeutic treatment. The results show that WM atrophy positively correlates and the ICD
negatively correlates with functional disability in PMD patients. Thus conventional MRI
provides a reasonable measure that can assist in a predictive outcome and the progressive
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development of disability. These findings indicate that this quantitative measure, including the
results is clinically relevant, gradable, objective and practical enough for inferring about the
pathogenesis of PMD. The presence of WM atrophy in excess of what might be expected for age
is well described in several WM disorders, predominately, in multiple sclerosis (MS) studies.
Atrophy is a clinically relevant entity in MS (Losseff and Miller 1998) and atrophy in the
cerebellum (Davie, Barker et al. 1995) has been correlated with ataxia. Studies that involve
WM, GM or both have shown a corroborating trend in the correlation with clinical
measurements of motor and cognitive disability. Volumetric atrophy, global or localized, have
been shown to correlate with clinical disability and cognitive scales in Alzheimer‟s disease
temporal lobe atrophy (Visser, Verhey et al. 2002), GM atrophy associated with cerebellar
function (Anderson, Fisniku et al. 2009), and thalamic atrophy observed in MS (Houtchens,
Benedict et al. 2007).
These findings are reproducible and relevant to PMD and can provide constructive
relationships between clinical disability and a non-invasive approach to monitoring progressive
changes as well as responses to therapeutic treatments. This study shows evidence that during the
natural progression of PMD; WM atrophy is a clinically relevant entity and is responsible in part
for the decline in functional disability in PMD. The severity of dysmyelination and atrophy of
pre-existing WM is dependent upon the type of PLP1 gene mutation, as it is a factor in assessing
the severity of myelin loss. It is naive to ignore the role axonal fibers play in the clinical and
pathological outcome in PMD and their impact on clinical disability. Most patients with PMD
lack primary axonal degeneration (Mar and Noetzel 2010), but some axonal loss has been found
in completely demyelinated areas (Gencic, Abuelo et al. 1989). Axonal damage has been
reported in patients with a null mutation (Garbern, Yool et al. 2002), as well as in PLP knockout
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mouse model (Griffiths 1998; Griffiths, Klugmann et al. 1998; Edgar, McLaughlin et al. 2003).
These studies exemplify the importance of interpreting WM pathology in the context of mutation
type with additional support that the absence of PLP, the major CNS protein is instrumental in
maintaining axonal integrity. Furthermore, animal models that experience natural occurring and
spontaneous mutations may show an occasional axonal spheroid, but the majority show well
preserved axonal fibers (Griffiths 1996). Transgenic mice engineered to carry extra copies of the
PLP1 gene serve as an experimental model for patients with duplications and reports show that
axonal degeneration is a significant pathological feature (Anderson, Schneider et al. 1998). The
cluster of PMD patients with duplications and triplications who exhibit the greatest decrease in
WMV and decline in FDS may reflect the involvement of axonal injury found in the transgenic
models. The findings are further supported by the observation found in patients with three and
five copies of the PLP1 gene that the level of expression is related to increased clinical severity
(Wolf, Sistermans et al. 2005).
As the disease progress to a more severe clinical phenotype, axonal injury may contribute
and become a contributing variable responsible for the decline in disability. Axonal loss is
widely accepted as contributing to the cause of neurological disability in MS (De Stefano,
Matthews et al. 1998) and correlates with the degree of inflammatory demyelination (Trapp,
Peterson et al. 1998; Trapp, Bo et al. 1999). Together, the lack of mature myelin, late stage
demyelination and axonal damage are variables that should be accounted for in white matter
pathologies and should all be evaluated to explain the strong linear correlation between WM
atrophy and FDS. Axonal pathology is well documented in CNS pathologies, most notably MS,
but is also observed in variety of myelin disorders (Bjartmar, Yin et al. 1999; Bjartmar and Trapp
2001; Mar and Noetzel 2010). In PMD, the extent of axonal injury increases with age and
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coexists with the infantile onset of PMD, thus accounting for the progressive neurologic signs in
PMD. Some axonal loss is evident; especially those axons that have undergone complete loss of
the very little existing myelin that originally encircled the axons, due to a lack of functional PLP
(Gencic, 1989). Most patients do not demonstrate signs of primary axonal pathology, however,
in both the PLP1 knockout mouse model and patients with a null mutation experience axonal
pathology that manifest in a length-dependent pattern (Garbern, Yool et al. 2002).
The simple linear measurement of the intercaudate distance may act as a surrogate
measure of cerebral atrophy, especially in PMD patients that have a severe dysmyelinated CNS
that causes the white-grey matter segmentation nearly impossible to differentiate. This simple
method has been utilized in monitoring and understanding the pathology of MS by measuring
brain atrophy as a marker for neuroaxonal loss and disease progression (Bermel, Bakshi et al.
2002; Caon, Zvartau-Hind et al. 2003) and is not only applicable to PMD, but other form of
leukodystrophies that have strictly a demyelinating pathogensis.

Conclusion
The clinical severity measurements and MRI volumetric findings are consistent with the
idea that white matter volume is inversely correlated with PMD severity. The correlation was
moderate, although highly significant. The diagnoses of cerebral white matter disorders was
revolutionized by the advent of MRI. Leukodystrophies were previously defined based on
autopsy pathological findings alone, but MRI has provided a powerful tool for investigating and
monitoring disease progression in living patients. The MR imaging findings in our patients are
compatible with diffuse hypomyelination of the cerebral hemispheres. Although significant
advances in the understanding and diagnosis of leukodystrophies using MRI have been made in
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the last decade, many problems remain. A substantial number of leukodystrophies remain
unclassified despite multiple investigations using clinical, genetic, biochemical, or imaging
studies. In addition, the common observation of abnormal white-matter signal on MRI (T2
hyperintensity) can reflect multiple different underlying pathologic changes, including acute or
chronic demyelination, inflammation, edema, or gliosis. Therefore, conventional MRI studies
might lack specificity. Because of this issue, there has been interest over the last few years in
alternative advanced magnetic resonance methodologies (in particular magnetic resonance
spectroscopy) that might provide more specific or complementary information regarding brain
structure and composition particularly to examine the role of axonal injury in a vast array of
white matter diseases.
Our data demonstrate that reduced white matter volume is likely one determinant of
neurological disability in PMD patients, while axonal dysfunction or loss correlates with clinical
progression, which is a late (typically post-adolescent) phenomenon. The findings in this study,
explicitly shows how the degree of WM atrophy appears to be dependent on the type of PLP1
mutation.
The use of MRI as a clinical tool to follow the natural history of PMD and incorporate its
application in the evaluation of future therapies is instrumental making this study and the
functional disability score assessment applicable to other forms Leukoencephalopathies.
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Figure 2.

Figure 2.1 (a) SPGR MRI outlining the brain parachyma excluding non-brain
structures (i.e. bone and dura matter), cerebellum and brainstem. (b)
Application of the color threshold highlighting the WM to be quantified. In
addition to subtracting CNS tissue and non-brain structures from the analysis,
the lateral ventricles and subarachnoid spaces also were excluded.
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Figure 2.2 Changes in white matter volume account for the change in
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Figure 2.3 Changes in white matter volume is not confounded by the
patient‟s age.
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Table 2. Functional disability score.
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Patient

Phys. #1

Phys. #2

Phys. #3

Phys. #4

Mutation

Deletion size
(kb)

BD
BC
KB
JB
MB
(#0007)
S
AD
(#0017)
JS
A1
A2
JR
MR1C
CM
ST
MS
SC
DC
PC
HB
GK

13
27
7
9
20

12
27
7
10
20

12
27
6
9
20

10
27
6
9
20

Duplication
DelG4 heterozygote
Del G4 male
Del G4 male
Del G4 male

330-890

14
4

14
4

13
4

12
4

unknown
Pro14Leu

5
27
27
14
16
20
16
2
4
6
16
27
9

5
27
27
14
15
17
14
2
4
7
16
27
8

5
27
27
16
15
17
16
2
4
6
16
27
8

5
27
27
16
15
20
15
2
3
6
16
27
7

Lys150Asn
Ile186Thr (rsh)
Ile186Thr (rsh)
duplication
duplication
Del 19 bp intron 3
Duplication
+3 IVS 6 (skips exon 6)
Duplication
Duplication
Duplication
unknown
Duplication

Table 2.1 Functional disability scores used for interrater reliability estimate

Pairwise
Rater
R1-R2
R1-R3
R1-R4
R2-R3
R2-R4
R3-R4

Pairwise
Correlation
0.99467
0.99086
0.95802
0.98935
0.99164
0.99696

Average Spearman
Correlation

5.9215

0.986916667

Table 2.2 Interrater reliability estimates

1320-2013
1320-2013
1020-1440
220-740
220-740
220-740
630-860
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Figure 2.4 SPGR MRI of three PMD patients with duplications of the PLP1 gene.
(a) normal myelination of the subcortical WM and internal capsule. (b)
Subcortical WM is isotense with a gradual decrease in hyperintensity of the
internal capsule. Patients FDS = 20. (c) Moderate thinning of the subcortical WM
with notable reduction in the temporal lobe. The internal capsule exhibits
significant hypointensity reflective of a substantial reduction to absent of WM.
Patients FDS = 12. (d) Diffuse reduction to absence of myelinated fibers with
moderate enlargement of the lateral ventricles and periventricular hyperintensities
representing preserved islands of myelin fibers. Patients FDS = 5.
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White Matter Volume (cm3)
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40

Functional Disability Score

Figure 2.5 Change in white matter volume account for the changes in overall
functional disability in patients with PMD.
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Figure 2.6 (a) Axial T1-weighted MRI of a normal myelinated brain. (b) FLAIR MRI of a
PMD patient with a delC279 frameshift mutation resulting in a nonfunctional truncated
PLP. The WM of the internal capsule is relatively normal with a slight reduction to
thinning of the subcortical WM. Patients FDS = 20. (c) Axial T1-weighted MRI of a PMD
patient with a P14L missense mutation. A uniform and diffuse reduction of cerebral WM
exemplified by a decrease in T1 signal intensity and marked reduction of the posterior limb
of the internal capsule with a corresponding increase in ventricular enlargement.
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0.2
Intercaudate Ratio (cm)

0.2

Duplications

0.1

Triplications

0.1
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Figure 2.7 The inter-caudate ratio increases as white matter volume decreases in
PMD and is a linear measure that changes in respect to a decrease in functional
disability.
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Figure 2.8 Sagittal T1-weighted MRI of corpus callosum in PMD. (a) Normal myelination.
(b) PMD patient with a complete deletion of the PLP1 gene. The corpus callosum WM is
relatively normal with a uniform thickness. Patients FDS =18. (c) Patient with a duplication
of PLP1 gene exhibits a severe reduction to absence of WM fibers of corpus callosum.
Patients FDS =9.

Area of corpus callosum (cm2)

7

6
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Figure 2.9 Corpus callosum area positively correlates with a decrease in patient
functional disability. Atrophy of the corpus callosum is an indirect measure of a
large white matter fiber bundle that is affected by dys/demyelination and axonal
loss.
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Table 2.3
PMD Patients

PLP1 Mutation

Age

Sex

FDS

ICD

WMV

B.D.
B.W.
J.E.
J.H.
J.S.
J.J.
N.C.
P.C.
T.B.
B.S.
C.E.
S.P.
B.H
J.R.
T.B.
T.B.
C.G.
T.F.
J.F.
J.F.
C.B.
T.K.
M.K.
T.D.
J.H.
J.H.
A.S.
G.W.
A.W.
W.M.
J.L.
M.G.
C.R.
J.T.
A.D.
M.E.
P.D.
H.B.
C.M.
J.E.
R.S.
A.S.
C.J.
J.S.

Duplication
Duplication
Duplication
Duplication
Duplication
Duplication
Duplication
Duplication
Duplication
X276W
delC279
delC279
K143X
del403-419
del403-419
del403-419
Deletion
DelG1/hetero
DelG1/hetero
DelG1
delG1/hetero
W144X/hetero
W144X
c.454-322G>A
Del 37E
F50V
C34R
G245W
H139Y
I186T
L80R
L80R
L84R
L86P
P14L
R136W
P14L hetero
P172S
R136G
X277W hetero
Y156H
Y206H
Y206H
V218F

10
3.5
11.9
10.8
16.2
6.5
3.8
43.9
40.5
10
23
11.8
16.2
18.9
35.5
35
14
40
15.6
18.5
47
46.1
23.4
NA
1.8
2.9
8.2
4.7
8.9
45.6
5.2
7.9
3.7
1
23.1
12
40
4.1
12
26.4
NA
2.1
28.3
25.5

M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F
F
M
F
F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F
M
M
M
M
M
M
M

12
12
9
20
5
15
9
16
16
25
20
21
25
18
9
25
18
32
32
20
30
29
25
11
4
5
2
6
27
30
4
4
10
5
4
32
32
6
14
32
13
30
25
15

0.09
0.15
0.10
0.12
0.16
0.10
0.10
0.14
0.10
0.09
0.09
0.06
0.09
0.13
0.15
NA
0.11
0.12
0.11
0.08
0.11
0.12
0.07
.12
0.11
0.10
0.11
0.14
0.05
0.08
0.08
0.12
0.10
0.10
0.08
0.1
0.08
0.16
0.08
0.09
0.09
0.10
0.10
0.12

.21
.26
.26
.26
.24
.32
.44
.31
.25
.40
.27
.42
.57
.35
.25
.36
.44
.47
.44
.41
.40
.48
.43
.55
.51
NA
NA
NA
.42
.46
NA
NA
.49
NA
NA
NA
.50
NA
.39
.46
.38
.39
.39
.32

CCV

NA
1.84
2.21
2.14
3.06
2.26
2.23
2.38
2.76
1.39
1.5
1.79
5.92
2.11
3.23
NA
4.62
4.83
3.84
3.06
4.83
6.49
4.11
2.7
2.9
4.1
NA
NA
NA
5.01
NA
NA
2.85
NA
NA
3.86
6.5
NA
3.86
NA
3.11
5.41
4.69
1.79
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A.J.
C.S.
J.H.
M.H.
R.H.
T.H.
P.G.
S.G.
C.S.
M.S.
P.S.
Z.B.
C.M.
J.S.
N.T.
H.B.
M.P.

Y206H/hetero
Y206H/hetero
p.226S>P
p.226S>P
p.226S>P
p.226S>P
X278C
X278C
IVS6+3G>T
IVS6+3G>T
IVS6+3G>T
IVS6-1G>T
IVS3 del+28-+46
Triplication
Triplication
NOT PMD
NOT PMD

57.6
34.2
56.6
31.1
45.8
28.1
35.2
38.4
49
23
25
3.8
12.3
NA
1
51.4
25.4

F
F
F
F
M
M
M
M
F
M
M
M
M
M
M
M
M

32
32
32
32
30
29
31
31
30
3
3
11
20
6
4
31
32

0.11
NA
0.10
0.12
0.10
0.10
.11
.10
0.1
.16
.13
.09
0.10
0.11
0.13
0.10
0.10

.43
.41
.58
.47
.51
.49
.27
.37
.35
NA
NA
.34
.46
NA
NA
.55
.40

NA
NA
NA
NA
NA
NA
5.0
4.7
NA
NA
NA
5.14
6.17
NA
2.36
5.68
5.84
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CHAPTER 3
ALTERED WHITE MATTER MICROSTRUCTURAL
INTEGRITY REVEALED BY DIFFUSION TENSOR IMAGING
IN PELIZAEUS-MERZBACHER DISEASE

The central nervous system (CNS) undergoes profound developmental changes during
the first few years of life that provide the structural and functional elements necessary for normal
neurological development. The maturation of white matter (WM) pathways, which are dependent
on the process of myelination, is critical towards the development of the nervous system(van der
Knaap, Valk et al. 1991). Dysmyelinating disorders or leukodystrophies comprise those disorders
in which myelin is not formed properly, or when myelin formation is delayed or arrested (van
der Knaap and Valk 1995). Failure to myelinate produces deficits in motor, sensory and
cognitive function due to impairment, or interruption, in the connectivity of WM pathways to
various gray matter regions. The underlying pathology of a neurological disease may involve
axonal injury, myelin degeneration, or both. An accurate and non-invasive evaluation of the
underlying WM pathology is crucial for diagnosing and monitoring clinical disease progression
and responses to therapeutic intervention.
Owing to its high sensitivity, magnetic resonance imaging (MRI) is the primary
neuroimaging modality used to detect and characterize white matter abnormalities in patients
with leukodystrophies (Cheon, Kim et al. 2002) but has not been shown to provide insight into
the underlying WM pathology and provide an examination of the microstructural properties of
the CNS tissue. The development of diffusion tensor – magnetic resonance imaging (DTI-MRI)
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allows a greater degree of sensitivity towards characterizing the effects of the neurological
disease on the cytoarchitecture of the CNS tissue. Because patients serve as their own baseline
reference, DTI makes it possible to follow subjects longitudinally to determine how the
microstructural properties change over time.
The diffusion tensor describes the magnitude, the degree of anisotropy, and the
orientation of diffusion anisotropy voxel by voxel, providing a unique way to study WM
architecture in vivo. Although this MR technique may be of diagnostic utility, it is currently
applied most often to characterize fiber tracts and serves as a biomarker for fiber integrity
(Werring, Clark et al. 1999; Ciccarelli, Werring et al. 2001; Le Bihan, Mangin et al. 2001).
Diffusion represents the translational motion of in vivo water molecules and is dominated by the
cytoarchitecture to probe the integrity and organization of the static neuroanatomy. In the CNS,
the diffusive properties of water depend on the local molecular and biochemical environment and
are restricted by microstructures, such as cell membranes, axons, myelin sheaths, extracellular
matrix and sub-cellular organelles, which include microtubules, microfilaments and proteins. In
particular, and unique to the CNS, is the compartmentalization of intra- and extra-cellular water
by the formation and cylindrical packing of the longitudinal array of axonal fibers. The pattern
of diffusion is dependent on the water‟s anatomical localization. In organized bundles of nerve
fibers, the net motion of water is greater parallel to the longitudinal axis than perpendicular to
them. This preferential directionality of diffusion is attributed to cell membranes of both axons
and the numerous lipid bilayer‟s of myelin. The relative effects of the different intra- and extracellular compartments on water diffusion in CNS white matter is still uncertain and debated, but
generally presumed to be dominated by the water within axons and that in the extracellular
spaces, which are also constrained by axonal and myelin membranes (Song, Sun et al. 2002;
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Peled 2007). The relative contributions of intramyelinic water and the periaxonal space to the
magnitude of water diffusivity is not fully established (Laule, Leung et al. 2006). Canavan
disease represents a global disturbance of cerebral water homeostasis with the development of
intramyelinic edema resulting from N-Acetyl Aspartoacylase accumulation in neurons increasing
water diffusion into the periaxonal space (Baslow 2000; Engelbrecht, Scherer et al. 2002; Patay
2005).
Many of the animal models of neurologic disease, in particular those of still unknown
cause, such as multiple sclerosis, Alzheimer disease, Parkinson disease and epilepsy are of
uncertain relevance to human disease although they may share some similarities with the human
conditions that they are meant to recapitulate. Induction of disease in these animals has
potentially non-specific and widespread effects that confound analysis and interpretation of
experimental results. For example, experimental autoimmune encephalitis (Gold, Hartung et al.
2000), regarded as the best model for multiple sclerosis, typically involves treatments that result
in variable degrees of inflammation, generation of reactive oxidative compounds, edema,
demyelination (Song, Yoshino et al. 2005) and axonal damage (Onuki, Ayers et al. 2001).
The analysis of animals with mutations affecting defined subcellular components of the
CNS, in contrast, provides powerful insights into the understanding the more important effects
on the diffusion of water in normal myelinated pathways as well as into changes in water
diffusion caused by disease pathology. Pelizaeus-Merzbacher disease (PMD) is an X-linked
disorder of the central nervous system (CNS), caused by a wide variety of mutations affecting
proteolipid protein 1 (PLP1), the major protein in CNS myelin (Hudson, Puckett et al. 1989;
Trofatter, Dlouhy et al. 1989; Raskind, Williams et al. 1991; Inoue, Osaka et al. 1999). PLP1 is
the major structural protein in CNS myelin, and is believed to form „adhesive struts‟ that bind
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adjacent lamellae of myelin membrane. (Boison and Stoffel 1994; Boison, Bussow et al. 1995).
The PLP1 gene is alternatively spliced and, in addition to PLP1, also encodes the internally
truncated DM20 protein, which lacks 35 amino acids from the intracellular loop (Nave, Bloom et
al. 1987). These proteins are targeted to the oligodendrocyte cell membrane. Although the
precise molecular and cellular functions of PLP1 and DM20 remain incompletely understood,
they are thought to be important for maintaining compaction of the myelin sheath in the CNS
(Boison, Bussow et al. 1995; Klugmann, Schwab et al. 1997). Since PLP1/DM20 are restricted
to oligodendrocytes, the myelin forming cells of the CNS, PMD and its excellent animal models
(Nave, Schneider et al. 1995; Yool, Edgar et al. 2000) provide highly specific systems with
which to evaluate the effects of disturbance of a single cell type on the structural and functional
integrity of the nervous system.
A wide variety of PLP1 mutations, both naturally occurring and experimentally
generated, have been reported in humans and a variety of other mammalian species (Yool et al,
2000). Somewhat surprisingly, complete lack of PLP1 results in a relatively mild phenotype,
both in rodents and in humans. Targeted inactivation of the murine PLP1 gene results in little
neurologic abnormality until adulthood, and morphologically is characterized by a subtle
increased spacing between adjacent lamellae of myelin membranes (Boison and Stoffel 1994;
Klugmann, Schwab et al. 1997; Rosenbluth, Nave et al. 2006), presumably due to loss of
interlamellar adhesion mediated by PLP1/DM20. PLP1-null human patients, have a surprisingly
mild phenotype characterized by relatively good early neurologic development which is followed
by progressive neurologic deterioration during adulthood (Klugmann, 1997; Garbern, 1997;
Garbern, 2002). In both mice and humans lacking PLP1, the late deterioration is characterized
most strikingly by axonal degeneration rather than by loss of myelin.
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The most common mutation that causes PMD is complete duplications of the PLP1 gene,
which is presumed to cause overexpression of PLP1 and DM20. In experimental systems, PLP1
overexpression results in aberrant PLP1 processing, with ectopic compartmentalization of Plp1
with cholesterol and disturbed assembly of myelin membrane (Simons, Kramer et al. 2002;
Karim, Barrie et al. 2007). PLP1 missense mutations, in contrast, span the full clinical range of
syndromes, from very mild „pure‟ spastic paraparesis to fatal „connatal‟ PMD. Severity of the
missense mutations is thought to arise in part from accumulation of unfolded PLP1/DM20 that
leads to varying degrees of oligodendrocyte apoptosis that is triggered by activation of the socalled unfolded protein response pathway (UPR) (Gow, Friedrich et al. 1994; Gow and Lazzarini
1996; Gow and Lazzarini 1996; Southwood, Garbern et al. 2002). Although there are currently
no disease-specific therapies for PMD, there are several strategies that are hoped to lead to
effective treatment of this severe disorder (Garbern 2007), and evaluation of future clinical trials
will require robust clinical and laboratory tools with which to evaluate patients.
In most cases, conventional MRI shows an arrest of myelination. T 2-weighted images
present a high signal intensity of unmyelinated white matter structures, whereas these structures
have low signal intensity on T1-weighted images. In „severe‟ connatal PMD due to missense
mutations, the brain is severely hypomyelinated which suggests thin to complete absence of
myelin. Classical PMD cases exhibit a less pronounced myelin deficiency. There is a patchy
absence of myelin with preservation of myelin islets giving the white matter the classical 'tigroid
pattern'. Mild PMD involves patients with a null mutation, where relatively a normal amount of
myelin develops with the abnormalities involving the intraperiod line.
The objective of this study was to perform DT-MRI and to quantify separately the
parallel and perpendicular diffusivities of major white-matter tracts and to compare these values

52
to those of age-matched normal control subjects. We hypothesize that patients with PMD
experience severe dysmyelination of white-matter structures without significant axonal damage
at least initially and the severity of this disease correlates positively with degree of
dysmyelination.
Furthermore, to supplement our study, we categorized the 12 PMD patients into three
groups [i.e. null (3), mild (5) and severe mutations (4)] representing the degree of mutation
severity affecting the PLP1 gene. This supplemental investigation is on-going and the analysis of
additional patients with genetically confirmed PMD will strengthen the principle that correlating
the known PLP1 gene mutation, which dictates the onset and severity of PMD, with the
diffusivity markers are instrumental in our understanding of the pathogenic mechanism of the
disease. The objective is to use DT-MRI and quantify the parameters or indices (i.e. parallel and
radial diffusivities) to examine the six white matter structures and to correlate the quantified
results to the pathogenic pattern observed in PLP1 mutations.

Methods and Materials
Subjects and clinical evaluation

Twelve male patients with PMD, aged 2 to 45 years of age, were compared to a group of
twelve age-matched healthy subjects free of neurological disease. Genetic analysis of their PLP1
genes revealed: #1: Y206H; #2: IVS6-1G>T (causing exon 7 skipping); #3: L84R; #4: P173S;
#5: G245W; #6: L80R; #7: Deletion; #8: del 403-419 (causes frame shift at residue 135); #9:
P.226S>P; #10: X278C; #11: X278C; #12: P.226C.
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Image Acquisition
MRI studies were performed on a GE 1.5 Tesla Sigma Excite (GE Healthcare,
Milwaukee, Wisconsin) and standard head coil. The MRI exam includes (1) volumetric T1weighted images utilizing a 3D magnetization preparation spoiled gradient echo (SPGR)
sequence, (2) Coronal fluid attenuation inversion recovery (FLAIR) images, (3) high resolution
morphologic axial T2W fast spin echo series, and 4) diffusion weighted spin-echo echo planar
images. The DT-MRI sequence consists initially of an image volume with no diffusion weighting
(b = 0 [s/mm2]) followed by the acquisition of image volumes in 6 gradient in non-collinear
directions with a b-value of 1000 [s/mm2]. For each b-value and gradient direction, 6 images
were acquired and magnitude averaging was used to reduce artifacts and to increase signal to
noise ratio. The total imaging time for the entire DT-MRI sequence is 9 minutes.

Diffusion tensor image data processing and analysis
Six brain white matter structures were chosen for analysis: anterior-limb of internal
capsule (ALIC), posterior-limb of internal capsule (PLIC), genu of corpus callosum (GCC),
splenium of corpus callosum (SCC), base of the pons (PO), and cerebral peduncle (CP). The
PLIC, PO and CP represent proximal to distal components of the major motor pathway, the
corticospinal tract. This approach of parallel and perpendicular diffusivity components have been
used to evaluate myelin loss and axonal injury (Song, 2002; Song, 2003; Budde, 2007). Regions
of interest (ROI) were manually drawn on directionally color-encoded (DCE) maps at the edge
of each structure to minimize partial voluming effect (Fig 3). Subsequently, these ROIs were
automatically copied on the three axial views of main, middle and minor eigenvalues maps
because approaches that exploit the ADC or FA have not resulted in improved specificity for the
underlying pathology in WM disorders (Budde, 2007). After identifying the structures, areas of
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interest were selected over at least 3 adjacent slices and averaged to obtain mean and standard
deviation (SD) values of all eigenvalues
radial diffusion (

= (

2

+

3)/2),

1

2

and

3.

Values of parallel diffusion (

1

=

),

ADC and FA were then calculated on each ROI for the

patients and normal controls and averaged to obtain a mean value for each group.
In these selected white matter structures, the diffusion parallel to the neural tracts and the
mean of the two other eigenvalues that is related to the diffusion perpendicular to the tracts,
which reflects the water movement across the fibers were recorded. Maps of

1,

2,

3,

ADC and

FA were obtained after tensor diagonalization using DTI studio software (H. Jiang and S. Mori;
Department of Radiology, Johns Hopkins University, Baltimore, MD) ROI based measurements
of these were analyzed separately to provide a more direct assessment of the directional diffusion
changes associated with white matter of PMD patients. Based on previous DT-MRI evidence
demonstrating that derived parallel and perpendicular diffusivities can detect and separate axonal
from myelin damage (Song, Sun et al. 2002; Harsan, Poulet et al. 2006; Harsan, Poulet et al.
2007), we measured separately the three eigenvalues.
For the ALIC, PLIC and CP since the side-to-side differences were not significant at p <
0.05 using a simple Pearson correlation test, the left and right sides were combined.
The between-two-groups statistical comparison was carried out separately for each
structure with a post-hoc repeated measures with multiple analysis of covariance (MANCOVA)
using age as covariate, and Boneferroni correction. Group differences with p < 0.002 were
considered significant. Age of the subjects was included as a covariate, because previous studies
have reported age-related increases in FA and decreases in ADC (Schmithorst, Wilke et al. 2002;
Snook, Paulson et al. 2005; Bonekamp, Nagae et al. 2007).
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Results
In this study of twelve patients with genetically confirmed PMD, the quantitative
difference among the six white matter structures between the two groups (PMD vs. NC subjects)
validates the supportive and sensitive role of DTI-MRI to probe and characterize the
microstructural changes that accompany the pathogenic process found in PMD.

Detailed

measurements of diffusion tensor characteristics demonstrated that the most sensitive parameter
to measure myelin pathology is radial diffusion and to a much lesser extent axial diffusion (Table
3; Fig 3.1). The percentage increase (Table 3) demonstrated that the most sensitive DT-MRI
parameter to measure microstructural abnormalities was the radial diffusion that showed an
increase in values (

= 76%, 109%, 25%, 43%, 36%, and 17% respectively) and were higher

than those in the axial direction (

//

= 8%, 13%, 8%, 6%, 11%, and 6% respectively). As

expected from the ROI-based analysis the increase freedom of radial diffusion due to the
dys/demyelinated axonal fibers was proven to be significantly higher (P=<0.001) in the studied
white matter structures in PMD. Axial diffusion is the descriptive parameter in describing the
architectural integrity of CNS tissue, particularly the myelin component which is the most
discriminating parameter for identifying myelin pathology.
The magnitude of water axial parallel to the axonal fibers in PMD patients showed a
relative mild to small significant difference when compared to normal control subjects (Fig 3.1).
This relatively insignificant change could be accounted for by the influence of the PMD subjects
who express a milder phenotype. Despite the overall non-significant change in parallel
diffusivity of water diffusion in the WM structures studied we noticed a significant increase in
the overall ADC values (Fig 3.2) in the patient group compared to control subjects. This
observation demonstrates the overwhelming increase of the radial component in water diffusivity
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and highlights the structural role of the myelin sheath as a sensitive marker to monitor the
progression of myelin pathology.
The tissue microstructure and architecture expressed by FA was significantly lower in the
ALIC, PLIC, GCC and SCC (p < 0.002) (Fig 3.2). Decreased FA was most marked in the SCC
and mildly significant in the ALIC, GCC and CP of PLP1 null mutations (Fig 3.4). These
observations suggest that abnormalities lie within the myelin, but do not exclude the proliferative
influences of the astroglial processes that become activated. Furthermore, the reduction in FA is
also driven by the significant increase in radial diffusion rather than axial diffusion where mild to
no significance was observed.
Deletion of the PLP1 gene causes a ‘mild’ form of PMD.
To further examine the overall impact myelin has on the diffusion markers, patients with
null mutations (Table 3.1) share an increase in radial diffusion (Fig. 3.3) in the studied WM
structures (

= 33%, 55%, 98%, 207%, 1.8%, and 58% respectively) and were higher than those

in the axial direction (

//

= 11%, .31%, 13%, 20%, -4%, and .68% respectively). This finding

provides a supportive explanation into the known pathogenesis suggesting that these types of
mutations which include either a compete deletion of the PLP1 gene or by frameshift mutation
causing a truncated PLP disrupt the ultrastructural integrity of the myelin sheath. Although
myelin is relatively spared early in the disease pathogenesis, the ultrastructural abnormalities are
due to the relaxed diffusional barriers imposed by the adjacent myelin leaflets creating a barrier
free extracellular space. This „pathologic space‟ resulting in a „radial component‟ allows the
aqueous fluid to flow where imposed barriers are relaxed and the myelin sheath is unable to
provide a unidirectional aqueous environment, consistent with compact myelinated fibers.
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The overall ADC was markedly increased (Fig 3.4) in the ALIC, PLIC, SCC (P=<0.01)
and is driven by the overwhelming increase in radial diffusion. The reduction in the FA was also
significant (Fig 3.4) in the ALIC, GCC, SCC and CP (P=<.05). The relaxed diffusion barriers
that exist between the adjacent myelin leaflets in null or functionally null mutations may also
explain the decrease in FA. PMD patients expressing mild mutations expressed little difference
in FA, indicating that myelin thickness is not a major contributor, but may involve minor
influences to anisotropy.
PLP1 missense mutations causes a ‘severe’ form of PMD
Patients with „severe‟ missense mutations share an increase in radial diffusion in the
studied WM structures (Table 3.2; Fig 3.6). The percentage increase demonstrates that the most
sensitive DT-MRI parameter to interpret myelin architecture is radial diffusion, which showed an
increase in values (

= 35%, 55%, 78%, 139%, 44%, and 74% respectively) and were

substantially higher than those in the axial direction (

//

= 15%, 16%, 25%, 25%, 24%, and 27%

respectively) (Fig 3.7). As expected from the ROI-based analysis the increase freedom of radial
diffusion is due to the thinning to absence of myelin and was proven to be significantly higher
(P=<0.001) in the studied white matter structures in PMD (Fig 3.5; Fig 3.6). Furthermore,
consistent with the findings of those with a null mutation ADC also increased particularly in the
ALIC, PLIC, Po (P=<.01) SCC and CP (P=<.05), whereas FA decreased markedly in the ALIC
(P=<0.01) and more mildly within the PLIC and CP (P=<0.05) (Fig 3.7).
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Discussion
A number of neurological disorders involve white matter pathology leading to myelin and
axonal dysfunction. Determining whether a particular disease is a result from myelin pathology
alone or involves axonal changes that encompass degeneration and/or spheroid abnormalities
cannot be depicted from a neurological examination alone. The advent of magnetic resonance
imaging has become the principle imaging modality in patients with inherited neurodegenerative
disorders and is instrumental in the identification, localization and characterization of white
matter abnormalities. A particular MR imaging technique that demonstrates an elevated
sensitivity towards monitoring the natural progression of various leukodystrophies is DTI.
Diffusion imaging has been found to be superior to conventional anatomical MRI in
differentiating dysmyelinating disorders, such as Pelizaeus- Merzbacher disease from
demyelinating disorders, such as globoid cell leukodystrophy and Alexander‟s disease (Ono,
Harada et al. 1995; Ono, Harada et al. 1997) and provides a unique insight into tissue structure
and organization, potentially providing information about the size, orientation and tortuosity of
both the intra and extracellular spaces. Due to its inherent sensitivity to the disruption of
microstructural architecture, DTI complements conventional MRI methods in the evaluation,
progression and monitoring of therapeutic intervention of neurological disorders regardless of
etiology.
The present DTI investigation is the first in-vivo study, to our knowledge performed on
twelve PMD subjects that have PLP1 mutations ranging in clinical severity, providing a direct
characterization and assessment of myelin loss of brain white matter tracts. The cylindrical
packed axons and associated myelin affects diffusion anisotropy of water molecules; therefore,
we monitored its effect on brain axons using DTI to correlate the complexity of the effects of
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structural modifications in the white matter that cannot be obtained from conventional
relaxation-based T1-weighted, T2-weighted or FLAIR MRI. Our study examined the DTI
sensitive markers

//

and

, as well as ADC and FA parameters to assess the integrity of white

matter in this patient population.
In the developing brain, water molecules in the cerebral cortex move more radially than
horizontally (McKinstry, Mathur et al. 2002). This anisotropy disappears with maturation and
increases as the axons myelinate. Measurements assessing the radial component of ADC are
instrumental in assessing normal brain maturation and the early manifestations if an inborn error
is disrupting the normal pattern of myelination. Our analysis revealed findings that involved a
significant increase in water diffusivity perpendicular to the axon of six selected white matter
structures (ALIC, PLIC, CP, GSS, SCC, and Po) as measured by (

). This result yielded a

significant increase in the overall mean diffusivity quantified by ADC along with a significant
decrease in the fractional anisotropy expressed by FA index. The radial diffusion index in this
study corroborates with previous reported literature exhibiting the inverse correlation with the
amount of CNS myelin (Song, Sun et al. 2002; Song, Sun et al. 2003; Song, Yoshino et al. 2005;
Harsan, Poulet et al. 2006). Our results of increased

in PLIC (43%), ALIC (25%), CP (36%),

GCC (76%), SCC (109%) and Po (17%), are in agreement with the increased

observed in

other white-matter diseases such as the early phase of MS (Henry, Oh et al. 2003), white-matter
lesions (Budde, Kim et al. 2007), dysmyelinated animals (Song, Sun et al. 2002; Harsan, Poulet
et al. 2006), and ex vivo study on demyelinated cuprizone-treated mice (Song, Yoshino et al.
2005).
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Perpendicular (radial) diffusivity
Reduction of radial diffusivity during maturation is suggested to be attributed to
myelination as this modulates the diffusion anisotropy originating from cell membranes by
creating an additional barrier (Beaulieu 2002). Furthermore, the lack/disruption of myelin sheath
has been found to increase radial diffusivity without affecting axial diffusivity. These findings,
along with the histological observation of continuing white matter myelination into adulthood
support the fact that decrease in radial diffusivity reflects the myelination process (Bonekamp,
Nagae et al. 2007).
Radial diffusion contributes to two-thirds of the overall ADC value, and the remaining
1/3 is attributed to the parallel diffusion. Although there was a relatively small increase in
parallel diffusion in the white matter structures analyzed a significantly higher mean diffusion
(ADC) values in these structure was observed and this is a consistent finding within across the
PLP1 mutation subtypes. This means that despite a reduction of

by a factor of two-thirds, the

overall diffusion increased significantly, suggesting the severe dysmyelinated white matter in
PMD overcomes the small change observed in parallel diffusion. Radial diffusion increased in
patients with deletion of the PLP1 gene due to the relaxed barriers. Studies involving PLP1 null
mice and the addition of ferricyanide (FCN), an aqueous extracellular tracer demonstrated that in
thick myelin sheath, FCN filled the interlammelar spaces irregularly, whereas the thinly
myelinated fibers the inter-lamellar spaces are filled across the full length of the sheaths, with no
FCN present in normal myelin (Rosenbluth, Nave et al. 2006). The results of this study
demonstrating the tendency of the extracellular fluid to leak into the interlammellar space
demonstrating the existence of a “radial component” to myelin in the rodent model expressing
the null syndrome.
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Of the white matter structures studied, the genu and splenium of the corpus callosum
which serves as the major conduit of the white matter connecting the homologous cortical areas
exhibited an even greater increase in radial diffusivity compared to the other significant white
matter structures. Our study shows radial diffusion to be mildly reduced in patients with PLP1
null mutations, but still overwhelmingly significant compared to PLP1 missense mutations. This
finding may indicate that PLP null mutations retained an appreciable amount of myelin forming
a resistant barrier to the properties of radial diffusivity, whereas the marked loss to complete
absence of myelin PLP1 missense mutations allows the water molecules to cross the fibers
perpendicularly with more freedom, resulting in an increase in

values.

Modifications of the intracellular or extracellular spaces, as well as the abnormalities
contributed by astrocytic activation and may influence the radial component of water diffusivity.
The increase in radial diffusivity in the white matter and cerebellum in experimentally
demyelinated mice and in MS supports the correlation of

with of myelin pathology

(Ciccarelli, Werring et al. 2001; Filippi, Cercignani et al. 2001; Cassol, Ranjeva et al. 2004).

Parallel (axial) diffusivity
Our study showed a mild increase in parallel diffusion ( ). The destruction of
neurofibrils has been found to increase parallel diffusivity (Kinoshita, Ohnishi et al. 1999). Other
factors which have been proposed to affect parallel diffusivity include fiber coherence (Dubois,
Dehaene-Lambertz et al. 2008), and axonal injury, which in animal studies is associated with
reduction in axial diffusivity(Kim, Budde et al. 2006). Therefore, it is likely that changes in axial
diffusivity reflect complex interactions of multiple biological factors that drive it in different
directions.
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The increase in parallel diffusivity was observed in the ALIC, GCC, SCC in patients with
deletion of the PLP1 gene and the ALIC, PLIC, GCC and CP in severe mutations and maybe
related in principal to the relaxed diffusion barriers imposed by PLP and the dysmyelinating
pattern that is found in connatal PMD due to PLP1 missense mutations. The thinning to absence
of myelin modeled in connatal PMD most likely involves the progressive axonal pathology that
contributes to the neurological severity in PMD (Fig 3.5). These findings also are consistent
with the results of (Harsan, Poulet et al. 2007), showing an increase in parallel diffusion in the
corpus callosum and anterior commissure in the white matter in jimpy mice brains compared to
dysmyelinated oligo-TTK transgenic mice. These findings and those of this study reflect the
contribution of astrocytic hypertrophy to the elevation of these diffusion coefficients. Axon
fibers are relatively preserved during the initial phases of the pathogenesis for patients with
classical and connatal forms of PMD, but will eventually undergo late-onset changes similar to
patients that lack PLP1 as oppose to those that lack a functional PLP1. The majority of the PMD
population accounting for the „mild‟ classical form and „severe‟ connatal form in that order, the
complex structural three-dimensional cytoskeleton make-up of axons is intact and composed of
longitudinal arrays of oriented neurofibrils (i.e. microtubules and neurofilaments) that
presumably account for the anisotropic diffusion and presents a sufficient barrier to hinder the
radial component of water diffusion. It should not go without mention that the late-onset axonal
pathology is evident in duplications and point mutations and would intrinsically impose stress
and disrupt the arrays of neurofibrils. In cases that involve patients with deletion of the PLP1
gene, axonal pathology has been reported in patients and rodent models exhibiting focal axonal
swellings causing impairment of the anterograde and retrograde transport mechanisms (Griffiths
1998; Garbern, Griffiths et al. 2000; Garbern 2005) and may influence the parallel coefficient by
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decreasing the flow of water due to an increase in the intra-axonal hindrance imposed by the
enrichment of neurofilaments in swellings, accumulation of dense bodies, multivesicular bodies
and mitochondria (Bjartmar, Yin et al. 1999).
The respective contribution of the extracellular and intracellular compartments to the
measured ADC remains unclear. The cylindrical and parallel organization of the fibers explains
the presence of anisotropy prior to myelination, but to a lesser degree following myelination.
The diffusion coefficients have been shown to be influenced by several factors including the
axonal morphology (Brady, Witt et al. 1999; Harsan, Poulet et al. 2006), myelin integrity (Song,
Yoshino et al. 2005) as well as intra-axonal composition (Harsan, Poulet et al. 2006). An
amplification of parallel diffusion coefficients was found in Jimpy mice brain and are thought to
be contributed by hypertrophic astrocytes, because cytoplasm extensions of astrocytes follow the
axonal pathway longitudinally (Skoff 1976), and also in axonal injury and normal appearing
white matter of experimental autoimmune encephalomyelitis animal model (Budde, Kim et al.
2007).

Fractional Anisotropy
Most patients with PMD lack signs of primary axonal changes, but axonal injury is a
characteristic feature in a small number of cases and is suggestive to be specific to the nature of
the PLP1 gene mutation. Axonal pathology has been demonstrated to exist in a length-dependent
and late-onset pattern in PMD patients and animal models exhibiting the null mutation. The
severity of axonal injury increases with disease progression contributing to the decline in
neurological ability in PMD (Garbern, Cambi et al. 1999). Our DTI results indicate that changes
in axonal integrity are reflected by the decreased FA and are likely to be replaced by large
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structures with a higher degree of isotropism, which may either be axonal spheroids or
edematous spaces.
Prior to myelination, cerebral white matter development consistently demonstrates an
increase in isotropy followed by an increase in the degree of anisotropy with white matter
maturation as seen in neonates and infants. The diffusion changes are tightly linked to the degree
of cohesiveness and cylindrical packing of axonal fibers and reduced extra-axonal space, due to
the natural thickness of myelin as the white matter matures over time. In white matter, any
change in tissue orientation patterns inside the MRI voxel will result in a change in degree of
anisotropy (Le Bihan, Mangin et al. 2001). The FA estimated by the DT-MRI method provides
information about the arrangement of local tissue cytoarchitecture. The ability to evaluate the
separate contribution of the directional diffusivities to the assessed anisotropy gives information
about the factors that contribute to the abnormal fiber development or myelination abnormalities.
Furthermore, the decrease in FA reflects the nature of an intact CNS from a microstructural view
that describes the health and viability of the cytoarchitecture.
Our study found a disruption in WM microstructural organization as reflected by the
lower FA index (Table 3) in the anterior limb internal capsule (-14%), posterior limb internal
capsule (-19%), pons (-13%), cerebral peduncle (-16%), genu (-26%) and splenium (-32%) of
corpus callosum in the PMD group when compared to the healthy control group (Table 3). The
low FA observed in the white matter and cerebellum in dysmyelinated mice confirms the FA
sensitivity of myelin pathology (Filippi, Cercignani et al. 2001; Ciccarelli, Werring et al. 2003;
Cassol, Ranjeva et al. 2004). Detectable changes in FA of these structures indicate a disturbance
of developing fibers that project through these white matter areas (Huppi 2001; Drobyshevsky,
Song et al. 2005). The amplified decrease in FA may arise from the severe astrocyte hypertrophy
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detected in the brains of PMD patients. Astrocyte hypertrophy and oligodendrocyte death
accompanying the myelin deficit was shown to play a role in the amplification of water diffusion
coefficients in jimpy brains because cytoplasm extensions of astrocytes follow the axonal
pathway longitudinally (Skoff 1976). The degree of anisotropy that has been reported in previous
literature has shown how FA progressively increases with remyelinatioin after experimental
demyelination (Harsan, Poulet et al. 2006) and in remyelinated MS lesions (Tievsky, Ptak et al.
1999).

Conclusion
Inherited leukodystrophies represent a heterogeneous group of disease with a wide
spectrum of distinctive causes and the underlying genetic involvement is not fully understood
due to the variable phenotypic expression that one gene may express. Together, this adds a
considerable challenge in the diagnosis of leukodystrophies and is associated with substantial
morbidity and mortality in children. Significant advances and the understanding of inherited
leukodystrophies such as PMD have propelled the importance of neuroimaging techniques in
monitoring disease progression. The role of neuroimaging modalities in probing into the
microstructural substrate is not limited to DTI-MR alone, but also includes MRS which is
instrumental in deciphering the biochemical composition of the tissue. Neuroimaging
applications complement each other by highlighting the direct insight into the physical properties
and architectural organization of the CNS tissue. Diffusion imaging can make reasonable
assessments into the integrity of white matter connectivity and the associated pathological
conditions that perturb the higher organization of the CNS by monitoring the changes in
diffusion of water over the course of disease progression.
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Diffusion tensor imaging is particular adapted for analyzing white matter structures and
changes in water content associated with maturation or perturbed maturation as evident in
leukodystrophies. In the severe „connatal‟ form of PMD, the maturation process is perturbed as a
result of cytotoxic insults of misfolded PLP causing premature cell death of oligodendrocytes
resulting in their inability to myelinate axons. Our results provide supporting evidence that axon
fibers lack or have a thin layer of myelin creating a barrier free environment amplifying the
diffusion in a radial direction, due to a reduction in myelinating cells. In the mild form of PMD,
null mutations demonstrated a similar result, concluding that abnormalities involve the myelin
sheath, but the pathologic disturbances are found between the myelin leaflets marked by
increased distance between intraperiod lines that should be adhered together forming compact
myelin by PLP. This interlamellar space created as a result of a lack of PLP enables diffusion to
proceed in a radial direction.
Although elevated, axial diffusion was not a diffusion parameter that provided direct
insight into a particular subtype of pathology, but it did exhibit a strong correlation with the
observed astrogliosis and the enlarged extracellular space as a result of hypomyelination
(reviewed in Chapter 4). The results also provide concluding evidence that the density of axon
fibers is reduced resulting, thus amplifying axial diffusivity.
The decrease in FA which is a measure of white matter organization that commonly asses
the connectivity of the rich fiber bundles in PMD among other forms of leukodystrophies
demonstrated that the fibers were disintegrated. The results obtained from all the white matter
structures analyzed excluding the Pons demonstrated the accuracy of FA as a measure of the
multidimensional diffusion profile, but the regions of complex fiber-crossing may have a lower
FA than those areas of a predominant unidirectional white matter structure as in the corpus
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callosum. With this knowledge, interpretation must be carefully analyzed to reflect the complex
nature of the white matter structure of interest.
The interpretation of DTI must incorporate the specific PLP1 genetic mutation, which is
a definitive component that alters the pathologic characterization of the individual PMD
subtypes. Early detection of subtle changes in brain microstructure and the accurate assessment
of dys/demyelination of the CNS tissue using DTI have an important contribution towards the
diagnosis, monitoring and therapeutic treatment of PMD.
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mm /s]

mm /s]

mm /s]

ADC
mm2/s]

1.533 ± 0.153
1.616 ± 0.157

0.482 ± 0.110
0.754 ±0.215

0.260 ± 0.062
0.550 ± 0.150

0.758 ± 0.077
0.974 ± 0.150

0.722 ± 0.060
0.533 ± 0.111

1.533 ± 0.178
1.713 ± 0.226

0.450 ± 0.132
0.836 ± 0.264

0.258 ± 0.080
0.630 ± 0.244

0.747 ± 0.110
1.059 ± 0.206

0.738 ± 0.052
0.495 ± 0.149

1.072 ± 0.078
1.166 ± 0.073

0.531 ± 0.062
0.644 ± 0.062

0.330 ± 0.061
0.460 ± 0.081

0.644 ± 0.055
0.757 ± 0.058

0.608 ± 0.073
0.514 ± 0.078

1.156 ± 0.128
1.241 ± 0.123

0.436 ± 0.098
0.617 ± 0.053

0.227 ± 0.075
0.416 ± 0.096

0.607 ± 0.068
0.758 ± 0.070

0.770 ± 0.145
0.588 ± 0.086

1.008 ± 0.060
1.079 ± 0.132

0.620 ± 0.063
0.712 ± 0.102

0.332 ± 0.088
0.441 ± 0.112

0.653 ± 0.057
0.744 ± 0.107

0.481 ± 0.078
0.410 ± 0.072

1.246 ± 0.104
1.377 ± 0.140

0.594 ± 0.074
0.794 ± 0.183

0.394 ± 0.074
0.547 ± 0.180

0394 ± 0.081
0.906 ± 0.158

0.745 ± 0.061
0.502 ± 0.118

2

GCC
C
P
SCC
C
P
ALIC
C
P
PLI
C
P
Po
C
P
CP
C
P

2

2

ADC
ALIC
PLIC
GCC
SCC
Po
CP

%
8
6
8
13
6
11

P
0.004
0.10
0.04
0.01
0.14
0.01

%
25
43
76
109
17
36

P
<0.001
<0.001
<0.001
<0.001
0.01
0.001

%
16
20
30
43
11
22

FA

FA

P
<0.001
<0.001
<0.001
<0.001
0.02
0.001

%
-14
-19
-26
-32
-13
-16

P
0.001
<0.001
<0.001
<0.001
0.03
0.01

Table 3. The top panel, represent the mean and standard deviation (SD) values of all
eigenvalues
3)/2),

1

2

and

3. Values

of parallel diffusion (

1

=

), radial diffusion (

=(

2

+

ADC and FA were then calculated on each ROI for the patients and normal controls

The bottom panel, exhibits the percentage change and P-value between the patients and
normal control for each of the selected white matter ROI. Anterior limb of the internal
capsule (ALIC), Posterior limb of the internal capsule (PLIC), Genu of corpus callosum
(GCC), Splenium of corpus callosum (SCC), Pons (Po), Cerebral peduncles (CP).
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Figure 3.1 Left: Perpendicular (radial) diffusion 10-3 mm2/s. The patients demonstrate a
significant increase (<0.05) compared to the normal control subjects. Right: Parallel
(axial) diffusion 10 -3 mm2/s. Parallel diffusion exhibited a mild increase compared to
normal controls subjects.
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Figure 3.2 Left: Fractional aniostropy 10 -3 mm2/s. The patients demonstrate a significant
decrease (<0.05) compared to the normal control subjects. Right: Apparent diffusion
coefficient 10-3 mm2/s.
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mm /s]

mm /s]

ADC
mm2/s]

1.035 ± 0.083
1.147± 0.061

0.513 ± 0.120
0.664 ± 0.020

0.339 ± 0.124
0.503 ± 0.043

0.629 ± 0.102
0.772 ± 0.08

0.604 ± 0.141
0.467 ± 0.018

1.170 ± 0.100
1.173± 0.081

0.367 ± 0.144
0.628 ± 0.051

0.212 ± 0.130
0.449 ± 0.049

0.583 ± 0.124
0.750 ± 0.032

0.853 ± 0.153
0.531 ± 0.085

1.578 ± 0.180
1.508± 0.034

0.458 ± 0.063
0.779 ± 0.099

0.249 ± 0.053
0.563 ± 0.079

0.762 ± 0.033
0.950 ± 0.056

0.739 ± 0.066
0.481 ± 0.069

1.494 ± 0.085
1.703 ± 0.070

0.369 ± 0.036
0.968 ± 0.216

0.280 ± 0.120
0.763 ± 0.221

0.714 ± 0.053
1.145± 0.164

0.749 ± 0.061
0.415 ±0.131

0.981 ± 0.051
1.037 ± 0.052

0.615 ± 0.103
0.680 ± 0.040

0.369 ± 0.158
0.433 ± 0.033

0.655 ± 0.095
0.717 ± 0.036

0.447 ± 0.143
0.400 ± 0.026

1.250 ± 0.064
1.282± 0.061

0.584 ± 0.116
0.761 ± 0.053

0.401 ± 0.118
0.542 ± 0.074

0.745 ± 0.061
0.862 ± 0.057

0.627 ± 0.159
0.466 ± 0.043

2

2

mm /s]
ALIC
C
P
PLIC
C
P
GCC
C
P
SCC
C
p
Po
C
P
CP
C
P

2

FA

ADC
%
11
.31
13
20
-4
.68

ALIC
PLIC
GCC
SCC
Po
CP

P
<0.01
0.9
0.04
0.01
0.6
0.9

%
33
55
98
207
1.8
58

P
<0.001
0.01
0.04
<0.01
0.8
0.01

%
22
21
35
77
-1.1
-22

P
<0.001
<0.01
0.04
<0.01
0.8
0.01

FA
%
-16
-28
-35
-53
-10
-31

P
0.04
0.1
0.04
<0.01
0.2
0.01

Table 3.1: Null mutations. The top panel, represent the mean and standard deviation (SD)
values of all eigenvalues
(

=(

2

+

3)/2),

1

2

and

3. Values

of parallel diffusion (

1

=

), radial diffusion

ADC and FA were then calculated on each ROI for the patients and

normal controls The bottom panel, exhibits the percentage change and P-value between the
patients and normal control for each of the selected white matter ROI. Anterior limb of the
internal capsule (ALIC), Posterior limb of the internal capsule (PLIC), Genu of corpus
callosum (GCC), Splenium of corpus callosum (SCC), Pons (Po), Cerebral peduncles (CP).
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Figure 3.3: Null mutations. Left: Parallel (axial) diffusion 10-3 mm2/s. Parallel diffusion
exhibited a mild increase (ALIC, GCC, SCC) and decrease (Po) compared to normal
controls subjects. This finding may suggest the role of axonal pathology, particularly the
presence of axonal swellings providing a diffusion barrier. Right: Perpendicular (radial)
diffusion 10-3 mm2/s is significantly increased (<0.05) excluding the Pons.
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Figure 3.4: Null mutations. Left: Fractional Anisotropy (FA) 10-3 mm2/s exhibited an
increase compared to normal controls subjects. This finding supports the disruption of
the cytoarchitecture and arrangement of fiber Right: Apparent diffusion coefficient
(ADC) 10-3mm2/s. The patients demonstrate a significant increase (<0.05) compared to
the normal control subjects.
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Figure 3.5 Axial FA diffusion maps of PMD patients with „severe‟ PLP1 mutations. (a) 2
year 1 month-old patient with a Y206H mutation and a FDS (30). (b) 3 year 7 month-old
patient with a L84R mutation and a FDS (10). (c) 3 year 7 month-old patient with a L80R
mutation and a FDS (4). The FA maps in these three cases exhibit a high degree of
anisotropy diffusion (a) as expressed by the hyperintense areas in the white matter of the
corpus callosum, although a significant reduction in the thickness of the white matter
fiber bundle was observed and paralleled the regression in FDS. The posterior and
anterior limb of the internal capsule in case (b) and moderately in case (c) demonstrates a
low signal intensity reflecting areas of isotropic diffusion. The reduction in FA is most
likely related to disintegration of fibers, but a significant increase in water content
(edema) without any effect on the fibers themselves can give the same FA reading.
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mm /s]

mm /s]

ADC
mm2/s]

1.032 ± 0.034
1.192± 0.084

0.536 ± 0.020
0.693 ± 0.023

0.359 ± 0.019
0.519 ± 0.028

0.642 ± 0.018
0.801 ± 0.030

0.564 ± 0.032
0.467 ± 0.047

1.186 ± 0.047
1.379± 0.057

0.440 ± 0.009
0.640 ± 0.062

0.279± 0.022
0.475 ± 0.068

0.635 ± 0.017
0.832 ± 0.056

0.759 ± 0.027
0.614 ± 0.058

1.462 ± 0.036
1.802± 0.062

0.481 ± 0.008
0.740 ± 0.379

0.298 ± 0.010
0.647 ± 0.267

0.747 ± 0.014
1.063 ± 0.212

0.692 ± 0.011
0.556 ± 0.187

1.448 ± 0.081
1.822 ± 0.185

0.423 ± 0.061
0.873 ± 0.327

0.248 ± 0.062
0.731 ± 0.210

0.706 ± 0.031
1.142± 0.127

0.734 ± 0.040
0.487 ±0.184

0.980 ± 0.020
1.214 ± 0.175

0.617 ± 0.023
0.844 ± 0.063

0.373 ± 0.053
0.584 ± 0.031

0.657 ± 0.028
0.880 ± 0.071

0.436 ± 0.037
0.339 ± 0.070

1.188 ± 0.054

0.600 ± 0.033

0.402 ± 0.034

0.730 ± 0.034

1.513± 0.095

0.993 ± 0.226

0.750 ± 0.187

1.085 ± 0.162

0.582 ± 0.033
0.390 ± 0.122

2

2

mm /s]
ALIC
C
P
PLIC
C
P
GCC
C
P
SCC
C
p
Po
C
P
CP
C
P

2

ADC
%
15
16
25
25
24
27

ALIC
PLIC
GCC
SCC
Po
CP

P
0.01
<0.001
<0.01
0.02
0.1
0.02

%
35
55
78
139
44
74

P
<0.001
<0.01
0.2
0.03
<0.001
0.02

%
25
31
42
62
34
48

FA

FA
P
<0.01
<0.01
0.05
<0.01
<0.01
0.02

%
-17
-19
-19
-34
-22
-39

P
<0.01
0.02
0.3
0.08
0.1
0.02

Table 3.2: Severe mutations. The top panel, represent the mean and standard deviation (SD)
values of all eigenvalues
(

=(

2

+

3)/2),

1

2

and

3. Values

of parallel diffusion (

1

=

), radial diffusion

ADC and FA were then calculated on each ROI for the patients and normal

controls The bottom panel, exhibits the percentage change and P-value between the patients
and normal control for each of the selected white matter ROI. Anterior limb of the internal
capsule (ALIC), Posterior limb of the internal capsule (PLIC), Genu of corpus callosum
(GCC), Splenium of corpus callosum (SCC), Pons (Po), Cerebral peduncles (CP).
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Figure 3.6: Severe mutations. Left: Parallel (axial) diffusion 10-3 mm2/s. Parallel diffusion
exhibited a mild increase (ALIC, GCC, SCC) and decrease (Po) compared to normal control
subjects. This finding may suggest the role of axonal pathology, particularly the presence of
axonal swellings providing a diffusion barrier. Right: Perpendicular (radial) diffusion 10 3

mm2/s is significantly increased (<0.05) excluding the Pons.
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Figure 3.7: Severe mutations. Left: Fractional anisotropy 10-3 mm2/s. FA, exhibited a
mild increase (ALIC, GCC, SCC) and decrease (Po) compared to normal controls
subjects. This finding may suggest the role of axonal pathology, particularly the presence
of axonal swellings providing a diffusion barrier. Right: Apparent diffusion coefficient
10-3mm2/s is significantly increased (<0.05) excluding the Pons.
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CHAPTER 4
NEUROPATHOLOGY INVESTIGATION IN PELIZAEUSMERZBACHER DISEASE IN VARIOUS MUTATIONS OF THE
PLP1 GENE
In 1885, Friedrich Pelizaeus first identified a genetic disorder causing spasticity and
developmental delay (Pelizaeus 1885). Twenty-five years later in 1910, Ludwig Merzbacher
further described the neuropathology of 12 affected individuals related to the proband
(Merzbacher 1910). Together, Pelizaeus and Merzbacher identified the X-linked inheritance, the
neonatal features, and the hypomyelination of the central nervous system that characterize the
disease.
Pelizaeus-Merzbacher disease (PMD; MIM 312080) is classified as a dysmyelinating
disorder, in which normal myelination never occurs, as opposed to a demyelinating disorders that
often are the basis of other forms of leukodystrophies, in which normal myelin is later destroyed.
Over the years, comprehensive surveys of PMD and autopsy reports have provided valuable
insights into the clinic-neuropathologic understandings that have led to a distinct classification
(classical, connatal, transitional and variants) of PMD that is dependent upon the mutation in the
PLP1 gene (Seitelberger 1954; Zeman, DeMyer et al. 1964; Seitelberger 1970; Seitelberger
1995). At the present time, although valuable contributions have been made in describing the
neuropathologic pattern and pathogenic mechanisms underlying the distinct PMD classification,
nosological problems regarding PMD still remain. To minimize the problems and to continue
moving forward with a greater understanding of the heterogeneity pattern of the PMD, the best
diagnosis is accomplished by neuropathologic findings at autopsy in addition to a comprehensive
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genetic analysis. As described by (Seitelberger 1984), leukodystrophies are caused by different
morphological changes of the CNS. The pathological changes observed in PMD, consists of a
diffuse reduction and alteration of CNS myelin. The extent of myelin deficiency differs among
the individual subtypes or classifications highlighting the unknown influence imposed by diverse
mutational mechanisms of PLP. PMD is the most striking of the leukodystrophies particularly at
early ages showing the reduction of developing myelin that is characteristic of dysmyelinating
disorders.
The different PLP1 mutational mechanisms have different effects on oligodendrocyte
viability causing the reduction and alteration to CNS myelin. The understanding of the exact
mutational mechanism that is responsible for causing the underlying pathology of each PMD
subtypes is evolving, but a full understanding still remains. PLP1 duplications result in
overexpression of PLP1 and the excess protein and its assembled associates, cholesterol and
lipids, accumulate in late endosomes and lysosomes reducing the viability of oligodendrocytes
effecting myelination (Woodward and Malcolm 2001; Simons, Kramer et al. 2002). PLP1 point
mutations are associated with the severe form of PMD that causes misfolding of PLP resulting in
the failure to transport functional PLP to the oligodendrocyte cell membrane. The misfolded PLP
accumulates in the rough endoplasmic reticulum (RER), and activates an unfolded protein
response (UPR) which modulates the disease severity and includes the transcriptional activation
of chaperone genes and apoptosis (Gow, Friedrich et al. 1994; Gow, Friedrich et al. 1994; Gow,
Southwood et al. 2002). The ER stress is considered fatal for oligodendrocytes causing
premature cell death exerting a downstream „severe‟ effect on the ability to myelinate internodal
axonal segments (Gow and Lazzarini 1996). PLP1 null mutations are a complete opposite to
PLP1 duplications and many missense mutations, in which myelination proceeds as normal,
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oligodendrocytes are preserved forming relatively normal amounts of myelin. Patients with a
null mutation experience a relatively mild clinical phenotype during childhood that is classified
as mild PMD or complicated SPG2 (Raskind, Williams et al. 1991; Garbern, Cambi et al. 1997;
Inoue 2004). Mice with a functionally null PLP1 gene have functionally normal
oligodendrocytes that develop and assemble relatively normal thick myelin, however a late and
rapid progression characterized by length-dependent axonal degeneration of motor and sensory
tracts along with axonal spheroids are likely responsible for the rapid decline. Although the
underlying mechanisms, as previously mentioned, are not fully understood,

evidence does

support the structural role of PLP in maintaining axonal integrity and compaction of the adjacent
myelin leaflets. Absence of PLP paradoxically does not affect myelination. The variability in
disease severity is most likely the result of the difference in PLP processing, trafficking of
mutant PLP and gain-of-function mechanisms. Examining the neuropathology in conjunction
with the clinical history and genetic analysis will provide the infrastructure for piecing together
the pathogenesis that is characteristic of a heterogeneous disease such as PMD.
This chapter will focus on results obtained from brain autopsy cases of 4 male PMD
patients with confirmed PLP1 mutations that include: (1) duplication (overexpression), (2) Null
(complete deletion), (3) W144X (PLP-specific domain; mild clinical phenotype), (4)
IVS6+3G>T (severe clinical phenotype).
Material and Methods
Case reports
PLP1 duplication case
Case 1 is from a family previously described clinically, and died at 47 years of age,
respectively. He had classical PMD syndrome with understandable but dysarthric speech, spastic
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quadriparaesis and never ambulated independently. Voluntary movements were slow with
rigidity compromised by severe spasticity.
PLP1 null mutation
Case 2 had a complete deletion of the PLP1 gene and flanking genes on the Xchromosome as described in (Raskind, Williams et al. 1991). He was wheelchair confined from
late adolescence and developed progressive spasticity and dysarthria. He had severe spastic
quadriplegia during the last 5 years of life and lost speech 2 years before be expired at age 47
from aspiration pneumonia.
PLP1 point mutations
Case 3 was 50 years old male, respectively with a W144X mutation who had been
previously been described (Osaka, Kawanishi et al. 1995) and is considered to have mild PMD
or SPG2. This mutation resides in the later part of exon 3 (exon 3b), an internal splice donor site,
which is alternatively spliced out of DM20 (Nave, Lai et al. 1987).
Case 4 was a 25 year old male, respectively, who subsequently was discovered to have a
PLP1 point mutation that disrupts splicing, causing in-frame exon 6 skipping, with loss of 22
residues (Southwood, Garbern et al. 2002).

Pathological analysis
Histological staining and immunohistochemistry
Corpus callosum (CC) tissue was extracted from each of the 4 male PMD patients brain
tissue and a male control patients and tissue sections were embedded in paraffin blocks and the
remaining tissue was stored in 4% fresh paraformaldehyde solution. The paraffin-embedded
tissue was sectioned at 4µ stainined with routine hematoxylin-eosin (H&E), Luxol-fast blue
(LFB),
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fibrillary

acidic
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immunocytochemistry. Tissue was also prepared for 1µ semi-thin sections for toludine blue
staining (TB).

Immunocytochemistry was performed using immunoperoxidase staining

techniques to detect myelin basic protein (MBP), proteolipid protein (PLP-AA3), GFAP, and
non-phosphorylated neurofilament (NF-SM32).

Immunoperoxidase staining
The paraffin-embedded tissue was cut into 5µm thick sections and mounted on (+)
charged slides and dried for 1hr at 60°C. The tissue was deparaffinized with Xylene (3 changes)
and rehydrated through a series of graded ethanol (100, 95, 70 and 50%) to distilled water. The
tissue was blocked with endogenous peroxidase activity with 3% H 2O2 for 5 minutes at room
temperature. Epitope antigen retrieval was required, so the tissue was treated with 0.1M citrate
buffer and cooked in the microwave for 10 minutes on high power than cooled to room
temperature for approximately 20 minutes. The tissue was rinsed briefly in distilled water then
blocked with non-specific antibody binding by incubating in 5% serum/0.5% BSA in 1X PBS
[(Goat for monoclonal GFAP and MBP and Horse for polyclonals PLP and NF]. The primary
antibody [(PLP 1:200), (SMI32-NF 1:1000), (MBP 1:500) and (GFAP 1:1000)] was diluted to
the optimal concentration in 1X PBS and incubated overnight at 4°C. The tissue was washed (3
changes) over 5 minutes with distilled water. Biotinylated secondary antibody (Vector Labs)
was diluted in 1X PBS and applied [(1:200 for GFAP and SMI32-NF( Mouse)] and [(1:500 for
MBP and PLP (Rat)]. Applied 500µl of AEC substrate (Vector labs) was applied and tissue was
incubated for 30 minutes or until the tissue turned red which occurred at times after 15 minutes.
The tissue was washed in distilled water (3 changes) and then counterstained in Mayer‟s
Hematoxylin for 1 minute and washed in tap water. The tissue was then rinsed once in 0.2%
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100% NH4OH and then briefly in tap water. The tissue was then coverslipped using a waterbased mounting media.
Immunohistochemistry – Monoclonal Rat anti-AA3/PLP
Specimens were fixed in 10% Neutral Buffered Formalin followed by processing,
embedding in paraffin and sectioned on a rotary microtome at 5

thickness. Sections were

placed on slides coated with 2% 3-Aminopropyltriethoxysilane and dried at 56 C overnight. The
slides were subsequently deparaffinized in Xylene and hydrated through descending grades of
ethyl alcohol to distilled water. Slides were placed in Tris Buffered Saline pH 7.4 (Scytek Labs
– Logan, UT) for 5 minutes for pH adjustment. Epitope retrieval was performed using Citrate
Plus Retrieval Solution pH 6.0 (Scytek) in a vegetable steamer for 30 minutes followed by a 10
minute countertop incubation and rinsed in several changes of distilled water. Endogenous
Peroxidase was blocked utilizing 3% Hydrogen Peroxide / Methanol bath for 30 minutes
followed by running tap and distilled water rinses. Following pretreatment, standard avidinbiotin complex staining steps were performed at room temperature. All staining steps were
followed by rinses in Tris Buffered Saline + Tween 20 (Scytek). After blocking for non specific
protein with Normal Goat Serum (Vector Labs – Burlingame, CA) for 30 minutes; sections were
incubated with Avidin / Biotin blocking system for 15 minutes each (Avidin D – Vector Labs /
d-Biotin – St. Louis, MO). Primary antibody slides were incubated for 60 minutes with the
Monoclonal Rat anti-AA3/PLP diluted at 1:200 in Normal Antibody Diluent (NAD) (Scytek).
Tissue was incubated in biotinylated Goat anti-Rat IgG (H + L) prepared at 11.0 g/ml in NAD
incubated for 30 minutes; followed by R.T.U. Vectastain Elite ABC Reagent incubation for 30
minutes. Reaction development utilized Vector Nova Red peroxidase chromogen incubation of
15 minutes followed by counterstain in Gill Hematoxylin (Thermo Fisher – Kalamazoo, MI) for
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15 seconds, differentiation, and dehydration, clearing and mounting with synthetic mounting
media.
Immunohistochemistry – Polyclonal Rabbit anti-Glial Fibrillary Acidic Protein (GFAP)
Specimens were fixed in 10% Neutral Buffered Formalin followed by processing, embedding in
paraffin and sectioned on a rotary microtome at 4 thickness. Sections were placed on slides
coated with 2% 3-Aminopropyltriethoxysilane and dried at 56 C overnight. The slides were
subsequently deparaffinized in Xylene and hydrated through descending grades of ethyl alcohol
to distilled water. Slides were placed in Tris Buffered Saline pH 7.4 (Scytek Labs – Logan, UT)
for 5 minutes for pH adjustment. Endogenous Peroxidase was blocked utilizing 3% Hydrogen
Peroxide / Methanol bath for 30 minutes followed by running tap and distilled water rinses.
Following pretreatment standard avidin-biotin complex staining steps were performed at room
temperature . All staining steps are followed by rinses in Tris Buffered Saline + Tween 20
(Scytek). After blocking for non specific protein with Normal Goat Serum (Vector Labs –
Burlingame, CA) for 30 minutes; sections were incubated with Avidin / Biotin blocking system
for 15 minutes each (Avidin D – Vector Labs / d-Biotin – St. Louis, MO). Primary antibody
slides were incubated for 60 minutes with the Polyclonal Rabbit anti-GFAP diluted @ 1:300
(Dako North America – Carpentaria, CA) in Normal Antibody Diluent (NAD) (Scytek).
Biotinylated Goat anti-Rabbit IgG (H + L) prepared at 11.0 g/ml in NAD incubated for 30
minutes; followed by R.T.U. Vectastain Elite ABC Reagent incubation for 30 minutes. Reaction
development utilized Vector Nova Red peroxidase chromogen incubation of 15 minutes
followed by counterstain in Gill Hematoxylin (Thermo Fisher – Kalamazoo, MI) for 15 seconds,
differentiation, and dehydration, clearing and mounting with synthetic mounting media.
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Luxol Fast Blue-Hematoxylin & Eosin staining
The 5µ paraffin sections of corpus callosum were deparaffinized in Xylene and
rehydrated to 95% alcohol. The sections were placed in Luxol fast blue solution overnight in
oven at 56°C. The Luxol fast blue, 0.1% solution was made using 5.0g of Luxol fast blue
dissolved in 1L of distilled water and 10% Glacial acetic acid. The tissue was then rinsed in
95% alcohol to remove excess stain. The tissue was washed well in running tap water for
approximately 2-3 minutes. Slides were immersed in lithium carbonate solution (0.05% solution)
for approximately 20 seconds to begin differentiation. 0.25g of lithium carbonate was diluted in
500ml of distilled water. The tissue continued in 70% alcohol solution until white matter could
be distinguished. The tissue was then rinsed briefly in lithium carbonate solution and then put
through several changes of 70% alcohol solution until the blue of the white matter appears
sharply. Rinse thoroughly in distilled water followed by the immersion in Mayer‟s hematoxylin
for 3 minutes. Slides were washed in tap water for 5 minutes and washed in .025% ammonia
water for 1 minute for a blue nucleus. The tissue was washed will in running tap water for 5
minutes and then in distilled water. The tissue was stained in Eosin solution for 8 minutes,
following by dehydration in 2 changes of 95% alcohol and 3 changes of absolute alcohol.

Luxol Fast Blue staining
The 5µ paraffin sections of corpus callosum were deparaffinized in Xylene and
rehydrated to 95% alcohol. The sections were placed in Luxol fast blue solution overnight in
oven at 56°C. The sections were then rinsed in 95% alcohol to remove excess stain. The tissue
was washed well in running tap water for approximately 2-3 minutes. The tissue was immersed
in lithium carbonate solution for approximately 20 seconds to begin differentiation and continued
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in 70% alcohol solution until white matter can be distinguished. The tissue was then rinsed
briefly in lithium carbonate solution and then put through several changes of 70% alcohol
solution until the blue of the white matter appears sharply. The tissue was dehydrated in 2
changes of 95% alcohol and 3 changes of absolute alcohol.

Hematoxylin and Eosin staining
The 5µ paraffin sections of corpus callosum were deparaffinized in 2 changes in Xylene
at 10 minutes each. The tissue was rehydrated in 2 changes of absolute alcohol at 5 minutes each,
95% alcohol for 2 minutes and 70% alcohol for 2 minutes. The tissue was washed briefly in
distilled water and then staining with Mayer‟s Hematoxyln solution for 3 minutes. The tissue
was then washed in tap water and then place in .25% ammonia water until the slides turned blue.
The tissue was then washed in tap water for approximately 1 minute following by a rinse in
distilled water for 2 minutes. The tissue was rinsed in 70% alcohol and then counterstained in
Eosin solution for approximately 1 minute and then dehydrated in 95% alcohol for 2 changes and
then 3 changes for absolute alcohol for 1 minute each. The tissue was then cleared in 2 changes
of xylene, 3 minutes each. The slides were then cover slipped with mounting medium.

Bielschowsky Silver stain
The corpus callosum was fixed in 10% neutral buffered formalin. The paraffin embedded
corpus callosum tissue was cut at 5µ sections. The slides were deparaffinized with xylene and
hydrated to distilled water, following by 3 washings at 3 minutes each in distilled water. The
sections were placed in 20% working silver nitrate solution for 15 minutes at 37C. The
remaining silver nitrate was poured off at the end of the 15 minutes into a clean container and
saved. The tissue was washed in several changes of distilled water for 10 minutes.
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To the silver nitrate that was saved from Step #4, ammonium hydroxide (concentrated
58%) was added drop by drop while agitating the container continuously until the precipitate which
forms is completely dissolved. Since approximately 7.0 to 7.5 mls are required, 6.0 mls was added
at once; thereafter, the ammonium hydroxide was added drop by drop until the end point is reached.
The tissue was placed in ammoniacal silver solution for 8 minutes at 37C, followed by
placing the solution in to a clean container. The slides were placed in the working 1% ammonium
hydroxide solution for 3 minutes. To the ammoniacal silver, add 4 drops of developer followed by
microwaving for 40 seconds + 20 seconds and agitate at 70°C in water bath for 2 - 3 minutes.
Sections are to be agitated until they turn a golden brown color. The tissue was washed in 1%
ammonium hydroxide solutions for 2 minutes and then washed in distilled water for 1 minute. The
tissue was placed in 5% sodium thiosulfate for 3 minutes and then washed in 3 changes of distilled
water at 5 minutes each. The tissue was dehydrates through graded ethyl alcohols and cleared in
several changes of Xylene. The slides were then coversliped with permanent mounting media.

Results
Myelin and axonal pathology
PLP1 duplication case (case 1)
This case showed a similar appearance of dysmyelinated tissue to that found in other
cases with PMD. The corpus callosum was grossly thin, markedly dysmyelination reflecting a
substantial reduction of myelin. The staining pattern for myelin basic protein (MBP) (Fig. 4.1b),
proteolipid protein (PLP) (Fig. 4.1c) and toludine blue (Fig. 4.1d) showed a progressive decrease
in myelin composition. The primary defect in PMD is the myelin abnormalities, referred as
dysmyelinating, but the relatively thin myelin that has formed most likely breaks down
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undergoing the process of demyelination. In this particular case, demyelination of preexisting
myelin resulted in a characteristic pattern not reported in previous literature and is described here
as discreet aggregates or clumps of degenerative myelin products (Fig. 4.1b-f). The deposits of
myelin products appear to be concentrated within the extracellular space with a few found
intracellular as marked by a solid membrane surrounding the content. Most of the degraded
myelin products did not appear to be found within microglia or macrophages representing types
of scavenger cells. Furthermore, it appears on H&E staining that no other cells are proliferating
or congregating near the region of these aggregates (Fig 4.1f). This finding most likely marks the
time period during the pathogenesis that precedes the invasion of scavenger cells to engulf the
debris by phagocytosis. Axonal spheroids were not observed, but should not be excluded as an
occasional feature, as reported in Sima et al., (2009). Moderate to severe loss of
oligodendrocytes and marked astrogliosis were observed.

Although axonal injury is not a

consistent finding across the PMD spectrum, it is reported in patients and mice as previously
discussed

and

may

be

influenced

by

the

heterogeneity

of

PLP1

mutations.
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Null mutation case (case 2)
The case showed a similar pattern of myelin loss, but not due to disturbances in myelin
formation caused by glial dysgenesis resulting in the classical dysmyelinating pattern. Thinning
and density of the myelinated fibers were less pronounced than that of the duplication and
missense mutations. The staining of myelin with HE-LFB (Fig. 4.2c) and toludine blue (Fig. 4
.3c) was not severely reduced, although fiber density appeared to be reduced. Axons that did not
have any appreciable amount of myelin sheaths most likely experienced late demyelination
associated with axonal injury. In contrast to the duplication patient, the products that reminisce
that of the structural decomposition of myelin sheath was not observed. The white matter
displayed numerous spheroids (Fig. 4.2) and mild astrogliosis (Fig. 4.5e). Activated microglia
were occasionally observed as exemplified by their characteristic elongated cigar shape cell
morphology, but the only definitive way to identifying the state of microglia is using specific
antibodies to label such cells.

Missense mutation cases (case 3 & 4)
Both cases exhibited a severe loss to thinning of myelin consistent of a diffusely
dysmyelinated tissue with reduced oligodendrocytes (Fig. 4.2d-e). Both cases exhibited marked
astrogliosis (Fig 4.5c-d), but case 4 demonstrated an extensive network of astroglial process
acting as a space occupying lesion between the reduced dys/demyelinated axonal fibers (Fig
4.5d). Both cases exhibited a mark reduction in axonal density with an occasional spheroid being
found in case 4. Case 3 exhibited a diffuse pattern of numerous spheroids similar to the findings
of the null mutation in case 2. Microglia were occasionally observed suggestive of a mild
inflammatory response associated with active demyelination particularly in case 3 were
appreciable amounts of degenerative myelin sheaths were found clustered.

90

Discussion
In the present study, results was examined in white matter pathology of the corpus
callosum in brain autopsy cases of 4 male PMD patients with confirmed PLP1 mutations that
include: (1) duplication (overexpression), (2) Null (complete deletion), (3) W144X (PLP-specific
domain; mild clinical phenotype), (4) IVS6+3G>T (severe clinical phenotype). The observations
collected from this neuropathology study supports previously reported findings of the
progressive myelinopathy (Zeman, DeMyer et al. 1964; Seitelberger 1970; Seitelberger 1984;
Seitelberger 1995) and axonopathy that is characteristic of PMD (Anderson, Schneider et al.
1998; Griffiths 1998; Garbern, Yool et al. 2002; Deluca, Ebers et al. 2004; DeLuca, Ebers et al.
2004).
The classical form of PMD includes duplications of the entire gene accounting for 6070% of the patient base (Sistermans, de Wijs et al. 1996). Depending on the degree of PLP1
overexpression, experimental evidence involving transgenic mice indicates that gene expression
is dosage sensitive and can cause dysmyelination and a late-onset demyelination (Kagawa,
Ikenaka et al. 1994; Readhead, Schneider et al. 1994). These findings translate to human patients
with three or more copies of the PLP1 gene who exhibited a more severe form of PMD (Wolf,
Sistermans et al. 2005). The findings from these and other studies, implies that more than one
pathogenic mechanism is responsible for the disease process and clinical severity.
Seitelberger‟s seminal work that uncovered the neuropathologic characteristics of the
PMD subtypes described the classic form of PMD as a patchy appearance of relatively
conserved, but thinner than normal myelin with preservation of the axon structure (Seitelberger
1970). These findings are consistent in case 1 of a PMD patient with PLP1 gene duplication
reported in this study. LFB, MBP and PLP immunostaining exhibited axons that were
moderately myelinated with several fibers experiencing late-onset demyelination in the presence
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of numerous „myelin balls‟ representing degraded myelin products. As a result of this diffuse
pattern of „myelin balls,‟ robust microglia were observed discreetly as an enlarged elongated
nucleus suggesting the onset of an inflammatory response to the structural changes resulting
from the myelin pathology. These findings are also in concert with (Edgar, McCulloch et al.
2010) of PLP1 transgenic mouse optic nerve that showed high level microglia activation in areas
of demyelination and a low level of microglia activation in areas of dysmyelination, furthermore
(Tatar, Appikatla et al. 2010) also demonstrated that a large influx of microglia reactivity in PLP
transgenic mice. An occasional axonal spheroid and degenerative axons were observed, but was
not a regular consistent finding which may suggest that the robust activation of microglia, as
reported in inflammatory demyelinating lesion of MS, may influence the late-onset axonal
pathology found in PMD (Trapp, Ransohoff et al. 1999).
Early manifestations of pathologic changes begins at birth for the connatal form
interfering with the process of myelin formation caused by premature oligodendrocyte cell death
due to cytotoxic accumulation of misfolded PLP retained in the ER causing a reduced number of
mature oligodendrocytes. LFB, toludine blue, MBP and PLP all showed a significant decrease in
staining for myelin in PMD patients with a mild missense mutation (case 3) and severe missense
mutation (case 4). Case 3 and case 4 exhibited a marked increase in GFAP-positive staining for
reactive astrocytes as previously reported by (Ulrich, Kohler et al. 1983; Ulrich, Matthieu et al.
1983; Koeppen, Barron et al. 1988) and is a marker of CNS white matter injury. An
overwhelming proliferation of glial processes in case 4 appeared to occupy the vast extracellular
space that maybe described as a space occupying lesion, due to the reduced density of the
severely dysmyelinated axons. Myelin degradation products were more frequently identified in
case 3 suggesting that the axons were moderately myelinated preceding the active process of
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demyelination. Furthermore, the axons in case 4 were severely dysmyelinated with areas of no
appreciable amount of myelin detected.
Axonopathy was a common recurring observation found in case 3 that had a PLP-specific
nonsense mutation in exon 3B (W144X) and classified as a mild form of PMD or SPG2 (Hodes,
Blank et al. 1997; Cailloux, Gauthier-Barichard et al. 2000) and in case 2 of the patient with a
deletion of the PLP1 gene that is also classified as having a mild form of PMD. Both cases
exhibited numerous axonal spheroids and thinning of fibers. The axon abnormalities are not a
cause of demyelination, since myelin is intact and oligodendrocytes are viable, but the defect lies
in the oligodendrocyte-axonal interaction. Consistent with this finding, Garbern and colleagues
reported a significant reduction in NAA/Cr ratio in mice and patients using MRS and is
indicative of neuronal integrity (Garbern, Moore et al. 2002). These findings echoes prior reports
of axonopathy in PMD null mutations and in transgenic mice with low level increase in PLP1
expression (Anderson, Schneider et al. 1998) and explains the late-onset and relative rapid
decline in clinical disability compared to the early onset severe manifestation by PLP1 missense
mutations and the severity of high levels of increase PLP1 expression.
The inflammatory response imposed by the activated microglia found in case 3 may
explain the thinning of axons and numerous spheroids as mentioned previously, whereas the
complete absence of PLP1 has been reported not to cause CNS inflammation supporting the
maintenance role of PLP in maintaining axon integrity.

Axonal injury is most likely a

consequence of the inflammation around the axons in case 3, but the alternative view should be
considered as well suggesting that that demyelination is also a variable responsible for axon
pathology.
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Activated microglia were occasionally observed by their characteristic elongated
euchromatic nucleus in both PLP1 missense mutations marking the presence of an inflammatory
reaction that has been well documented in EAE mice and MS patients with inflammatory
demyelination (Bradl and Linington 1996; Bar-Or, Oliveira et al. 1999; Trapp, Bo et al. 1999;
Bradl and Hohlfeld 2003). The Inflammatory response detected in MS has been well described
as having a strong influence in controlling axonal pathology found in MS lesions and are
responsible for the irreversible neurological disability (Trapp, Peterson et al. 1998; Bjartmar and
Trapp 2001; Bjartmar, Wujek et al. 2003). These findings may have strong implications in
describing axonal pathology as it relates to neurologic impairment in PMD particularly in the
mild cases of PMD that express an appreciable myelin thickness and density of axons that are
now susceptible to demyelination marking the end-point in the pathologic progression.
Conclusion
Merzbacher originally described the absence of myelin sheaths specific to the CNS
without axonal involvement and preserved myelin islets around blood vessels. These patchy
areas of myelin islands give the tissue a "tigroid" appearance (Takanashi, Sugita et al. 1999).
Gross sections of the PMD brain reveal atrophy, pallor, and sclerosis of white matter in the
cerebrum, cerebellum, and brainstem (Gencic, Abuelo et al. 1989). The axons of the central
nervous system lack the typical myelin sheath. In addition, there is a profound loss of
oligodendrocytes, which produce myelin. The pathologic pattern of diffuse degraded myelin
aggregates, found in duplications is not a new finding as (Seitelberger 1970) described a similar
pathology in PMD called “myelin balls.” However, beyond the written description the exact
pathologic appearance has not been observed to my knowledge.
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Axonal damage is variable and found remarkable in particular cases of the PMD
subtypes. Axonal damage has been demonstrated, particularly in the null mutation and the mild
point mutation found within the PLP1 specific domain cause aberrant trafficking of PLP and not
DM20.

The presence of axonal spheroids was observed diffusely in both cases with an

occasional spheroid found in the severe missense and duplication patients that is likely due to
impaired axonal transport from altered proteolipid protein-mediated oligodendrocyte-axonal
interactions. This finding follows the pathologic thinking that white matter volume is a clinical
manifesting determinant, but axonal play an equal role that exhibits in a late-onset phenomenon.
Furthermore, the presence of microglia in the duplication patient, but also found in the mild and
severe point mutations suggest a causative role in regulating axonal viability as seen in MS
inflammatory demyelination lesions. This was not a prominent finding in the null mutation,
although should not be discounted as potential variable, but the late-onset axonal pathology
exhibited by degeneration and spheroids are caused by the dosage sensitivity of the PLP1 gene.
The results from this study, corroborates and supports the previous findings documented PMD
pathology, but this study also brings new information providing insight into the pattern and
progression of the disease pathogenesis.
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Figure 4.1 Pathologic changes in PLP1 duplication patient (case 1). (a) 60 year-old
control subject, who exhibits a normal density of myelinated fibers and distribution of
oligodendrocytes by immunoperoxidase-MBP staining. (b) Thinning of myelin and reduced
axonal fiber density with an increase composition of myelin degradation products using an
immunoperoxidase staining for MBP. (c) immunoperoxidase stain for PLP exhibiting
irregular non-uniform aggregates (arrows) of PLP a degradation product of myelin. (d)
Luxol-fast blue, (e) HE-LFB and (f) H&E staining provide conclusive insight into a window
a time of the pathologic product of demyelination (arrow) of the very thin pre-existing
myelin that formed. Scale 50 µm.
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Figure 4.2 PLP1 gene deletion. Numerous axonal spheroids (arrows) could be detected by light
microscopy under Bielschowsky silver stain (a, b) and H&E-LFB staining (black arrow) (c) and
were diffusively observed in the corpus callosum. Plate (a): scale10µm. Plate (b, c): scale 50µm.
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Figure 4.3 Toludine blue staining. (a) 60-year-old control subject with normal thickness and
distribution of axonal fibers. (b) Duplication (case 1): Diffuse dysmyelinating and decrease
in axon density. (c) Null mutation (case 2): Axons demonstrate relatively thick myelin
sheaths with structural abnormalities reflected in the „unraveled‟ morphology (artifact) due
to the absence of PLP and its innate ability to form compact myelin (black arrows). Axon
diameter appears relatively large and may suggest that some of the axons are swollen and
actively undergoing demyelination. (d) Severe missense mutation, IVS6+G>T (case 4) and
(e) Mild missense mutation, W144X (case 3) exhibits a uniform reduction to absence of
myelin and oligodendrocytes. Activated microglia are observed in the 4 cases suggesting an
ongoing inflammatory response to the pathologic changes of the white matter, particularly
during the destruction of myelin. Scale 50µm.
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Figure 4.4. Axonal pathology. (a) Bielschowsky silver staining of a normal subject with normal
distribution and density of axons. (b) Duplication (case 1). The density of axonal fibers is
relatively normal although axonal degeneration is likely to contribute towards the disease
pathogenesis. (c) Mild missense mutation, W144X (cases 3) and (d) severe IVS6+G>T (case 4)
exhibited a moderate reduction in axon density. The mild mutation W144X (plate c; case 3),
exhibited numerous swollen axons (arrows) with Bielschowsky silver stain, (e)
immunoperoxidase-MBP staining and with (f) H&E-LFB staining (arrows). Scale 50µm.
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Figure 4.5. GFAP stain. The characteristic and vigorous response of astrocytes to white
matter injury is a prominent feature observed in the 4 cases as reflected in the GFAP staining.
(a) 60 year-old normal control subject with non-reactive astrocytes. (b) Duplication (case 2)
has moderate gliosis, whereas, (c) the mild W144X missense mutation and (d) severe
IVS6+G>T missense mutation reflects an extensive array of gliosis occupying the space of
the substantially hypomyelinated corpus callosum. (e) Null patient (case 2) exhibits a mild
form of gliosis due to the presence of relatively normal thickness of myelin that was
sustained through the course of the disease. Scale 50µm.
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CHAPTER 5
CONCLUSION
Pelizaeus-Merzbacher disease is a dysmyelinating disorder, in which normal myelination
never occurs. Mutations of the PLP1 gene result in a range of phenotypes that form a clinical
spectrum, from the more severe PMD at one end, to the relatively mild X-linked spastic
paraplegia 2 (SPG2) at the other. Most cases (60-70%) of PMD are caused by duplication of the
PLP1 gene, which most likely causes overexpression of PLP, resulting in compromise of the
myelin sheath structure. Protein misfolding caused by PLP1 missense mutations is a second
likely pathogenic mechanism of PMD. A third mechanism involves null-mutations leading to a
loss of function in which no protein is produced. These cause relatively mild disease. The major
clinical features of PMD are nystagmus, spasticity, athetosis, tremor, and ataxia. The symptoms
vary in onset and severity, thereby producing a clinical spectrum of disease. Various forms or
phenotypes of PMD are distinguished by severity of disease and other clinical features.
The results of this study demonstrates that reduced white matter volume is likely one
determinant of neurological disability in PMD patients, while axonal dysfunction or loss is a late
post-adolescent phenomenon that contributes to the clinical and pathologic progression. The
clinical severity measurements and MRI volumetric finds are consistent with the speculation that
white matter is inversely correlated with PMD severity. The correlation was moderate, although
highly significant. Reduction in white matter volume may result not only from the
hypomyelination but also axonal loss. The surrogate marked to measuring the distance between
the caudate nucleus is a reliable method to implement when grey white matter segmentation is
not possible to delineate.
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Since the degree of myelination is relatively preserved in PLP1 null myelin, the increased
radial diffusion found using diffusion imaging is not the result of thinner myelin sheaths per se,
but the increased radial diffusion is more likely due to increased myelin water, due to decreased
compaction, which described the existence of a “radial component” to myelin, described in Plp1
null mice, created by aqueous channels that span the myelin sheath. Additional factors, such as
astrocytosis, may also contribute to the increased radial diffusion. It should also be mentioned
that a slight and insignificant increase in parallel diffusion may be accounted for by the parallel
arraignment of the glial processes of astrocytes that occupying the vast extracellular space due to
myelin loss. The results indicated that radial and parallel indices are sensitive markers of WM
pathology and the parameters may be sensitive to abnormalities that are not apparent on the
histological markers. The decrease in FA supports the pathologic findings that the architectural
arraignment is completely disrupted due to thinning to degenerative axons. This loss
compromised the density and sophisticated pattern that describes the trajectory of neural fibers
throughout the white matter. With previous knowledge and current findings, it is not a surprise
that an astounding decrease in FA was found across the heterogeneous nature of PMD. This data
supports the use of MRI as a clinical tool to follow the natural history of PMD, and potentially
for its application in evaluation of future therapies.
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APPENDIX A
ABBREVIATIONS INCLUDED IN THIS DISSERATIONS

PMD
PLP
CNS
UPR
MS
ER
ECM
MBP
IPL
MAG
GFAP
NF
GalC
FDS
PNS
PMP22
WM
WMV
ALIC
PLIC
Po
SCC
GCC
CP
DCE
FLAIR
MRI
DTI
MRS
DT-MRI
ADC
FA
FCN
OLG

pelizaeus-merzbacher disease
proteolipid protein
central nervous system
unfolded protein response
multiple sclerosis
endoplasmic reticulum
extracellular matrix
myelin basic protein
intraperiod line
myelin associated glycoprotein
glial fibrillary acidic protein
neurofilament
galactocerebroside C
functional disability score
peripheral nervous system
peripheral myelin protein
white matter
white matter volume
anterior limb internal capsule
posterior limb internal capsule
pons
splenius corpus callosum
genu corpus callosum
cerebral peduncles
direction encoded map
fluid attenuated inversion recovery
magnetic resonance imaging
diffusion tensor imaging
magnetic resonance imaging
diffusion tensor magnetic resonance imaging
apparent diffusion coefficient
fractional anisotropy
ferric cyanide
oligodendrocyte
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APPENDIX B

Functional Disability Rating Scale

Patient name: ____________________________________

Age: ________________ Date of birth:

Date of exam: ____________________________________

1

2

3

0 – no formal schooling; 1 – special school or special
education classes; 2 – regular classes, but not at grade
level; 3 – regular school, grade appropriate for age
(within 2 years)

* If beyond school age:
Employment
0

1

2

3

0 – unable to work/homebound; 1 – sheltered
workshop (i.e. works at institution dedicated to
disable employees); 2 – special job (i.e. works at
conventional workplace, but requires special
supervision); 3 – regular job

Speech

0

1

2

3

1

2

3

4

Dressing

0

1

2

3

0 – total dependence; 1 – Can assist with dressing but
dependent on others 2 – independent, but with
decreased efficiency; 3 – normal

Toileting

0

1

2

3

0 – total dependence; 1 – needs assistance; 2 –
independent, but with decreased efficiency; 3 –
normal

2

3

4

*Education

Feeding

0

0

Writing

0

1

Sitting

0

2

Walking

0

1

4

0 – no verbal communication; 1 – rare
understandable words with nonverbal
communication; 2 – speech understandable with
difficulty; 3 – detectable speech disturbance but
readily understood; 4 – normal speech

0 – tube feedings only; 1 – some oral feeding, with
supplemental tube feedings; 2 – oral feedings with
consistency changes to diet; 3 – normal diet with
occasional choking; 4 – normal swallowing

5

0 – cannot reach for and grasp writing utensil; 1 – can
point to correct letters on computer screen with hand
or mouse; 2 – can reach for and grasp writing utensil,
but cannot scribble; 3 – can scribble, but cannot draw
or write letters; 4 – can draw or write letters, but
difficult to read; 5 – normal for age

0 – cannot sit without support; 2 – can sit without support
2

3

4

5
0 – wheelchair or bedbound; 1 – can crawl/bunny
hop; 2– can walk a few steps, but needs adaptive aids
or other support; 3 – needs adaptive aids to walk 20
feet;
4 – impaired gait, but uses no assistive
devices; 5 – normal gait
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Breathing

0

1

Total Functional Disability Score:

Percentile (of scorable items) scores:

2

3

0 – ventilator or constant respiratory support; 1 –
intermittent use of non-invasive respiratory support;
2 – has respiratory symptoms but does not use
ventilatory support; 3 – normal breathing
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Myelin is a multilamellar membrane structure surrounding axons in both the CNS and
PNS that facilitates nerve conduction. In the CNS, myelin is synthesized by oligodendrocytes,
while in the PNS; myelin is synthesized by Schwann cells. In the CNS, Proteolipid protein 1
(PLP1), an integral membrane protein, is the major protein component of myelin, constituting
~50% of myelin protein. Mutations of the PLP1 gene in man cause a spectrum of neurological
disease, ranging from the severe Pelizaeus-Merzbacher disease (PMD), that typically begins
during infancy with nystagmus, seizures and hypotonia and evolves into spastic quadriparesis,
cognitive impairment and ataxia, to „pure‟ spastic paraparesis, that is characterized exclusively
by leg spasticity and weakness. The predominant pathological abnormality in PMD consists of
thinning to almost complete absence of myelin in the CNS. Gow and colleagues have proposed
that the severity of mutations that alter the structure of PLP1 (typically missense mutations)
correlates with the degree to which they cause protein misfolding, activate the unfolded protein

122
response, and cause oligodendrocyte apoptosis (Gow and Sharma, Neuromolecular Med 4:73,
2003). Implicit in this mechanism is that the degree of myelination should inversely correlate
with the degree to which oligodendrocyte apoptosis is activated. We speculated that the early
PMD phenotype predominantly is dictated by the effect on oligodendrocyte viability. In contrast,
we have found that complete absence of PLP1 in both mice and humans is characterized by wellformed myelin, but late length-dependent pattern of axonal degeneration (Garbern et al. Brain
125:551, 2002). We speculate that progression of disease correlates with the rate of axonal
damage. The goal of this study was to investigate whether non-invasive MR techniques to assess
extent of myelination and degree of axonal disruption correlated with measures of clinical
capacity. Furthermore we wanted to differentiate between axonal and myelin pathology using
diffusion tensor imaging as a reliable imaging modality to assess the effects of PLP1 mutations
on water diffusion in central nervous system (CNS) white matter. The most dramatic difference
between PMD patients and age-matched controls was increased λ , most marked in the corpus
callosum. Moreover, this was most prominent in patients with PLP1 null mutations. Increased
radial diffusion has been reported in dysmyelinating rodents, including the myelin synthesis
deficient rat (md) that has a severe Plp1 missense mutation. Interestingly, λ// was also increased
in the severely affected PMD patients, whereas in severely dysmyelinated rodents, the λ is
reported to be normal to decreased. λ// in patients with PLP1 null mutations was relatively
unaffected relative to controls. Since the degree of myelination is relatively preserved in PLP1
null myelin, the increased radial diffusion is not the result of thinner myelin sheaths. Therefore
the increased radial diffusion is more likely due to increased myelin water, due to decreased
compaction, and which may be in part due to the existence of a “radial component” to myelin,
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described in Plp1 null mice, created by aqueous channels that span the myelin sheath. Additional
factors, such as astrocytosis, may also contribute to the increased radial diffusion.
Genetic abnormalities affecting the PLP1 gene has been shown to cause axonal injury
and significant early-onset dysmyelination and late-onset demyelination. The exact mutational
mechanism remains to be described, although substantial progress had been made to make
reasonable assessments that may provide a better understanding towards the disease
pathogenesis. In the study involving autopsy tissue from genetically characterized patients has
provided valuable information that describes the changes in the structural architecture of the
tissue over time. These pathologic changes corroborate with the findings from the diffusion
imaging making these two methods extremely reliable for describing the pathologic state as each
patient experience a slightly different pathogenic course that is dependent on the exact PLP1
mutation.
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